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SWEET SORGHUM (SORGHUM BICOLOR) BIOMASS, GENERATED FROM BIOFUEL 




 Sorghum bicolor is the fifth most cultivated cereal crop worldwide1. Varieties of S 
bicolor, known as grain sorghum, are cultivated for human food and animal feed. Certain 
varieties, known as sweet sorghum, concentrate sugar in the pith cells of the stalk and are 
cultivated for sugars and syrups. Recently, interest has grown in the use of sweet sorghum as a 
feedstock for biofuel production. This is due to reduced water requirements, shorter growing 
periods and reduced cultivation cost when compared to other feedstocks1. Biofuel production of 
sweet sorghum generates large masses of biological wastes, comprised of stalks, leaves, leaf 
sheaths and seed heads2. This biomass could serve as a potential reservoir for bioactive 
compounds for human health. Rich in phenolic acids and flavonoids, these parts of the sorghum 
plant have been used as a traditional medicine in African and Asian cultures for the treatment of 
various disease states, including cancer3. Furthermore, recent studies have elucidated in vitro and 
in vivo antiinflammatory, antioxidant, and anticancer activities of the seed head, leaf and leaf 
sheath4–11. Much less is known about the in vitro and in vivo bioactivities of the stalk 
components of sweet sorghum varieties. Here, the in vitro anticancer activity, and the in vivo 
antiinflammatory and antioxidant activity of sweet sorghum with a focus on the dermal layer, a 
component of sweet sorghum stalk, were investigated. It was hypothesized that the dermal layer 
contains phenolic compounds with antiproliferative, proapoptotic and 
iii 
 
antiinflammatory/antioxidant properties. Given the high rates of cancer incidence and mortality, 
as well as the close connection to a Western diet, in vitro colon cancer cell models and in vivo 
Western diet induced obesity and oxidative stress models were utilized for the purposes of this 
study.  
 For in vitro studies, the colon cancer HCT116 cell line and colon cancer stem cells 
(CCSCs), and their p53 variants HCT116 p53-/- and CCSCs p53 shRNA, were treated with 
different doses of phenolic rich extracts from the stalk components (pith and dermal layer), the 
leaves, and the seed head. Phenolic compounds are ubiquitous throughout the plant kingdom, 
consistently display bioactivity, and their antioxidant activity has been linked to the anticancer 
activity of phenolics. Total phenolics and antioxidant activities were determined by the Folin-
Ciocalteu and 2,2`-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assays, 
respectively. Individual phenolic compounds were identified by LC-MS analysis. Increased 
proliferation and suppressed apoptosis are two important hallmarks of cancer and are commonly 
targets of anticancer therapies. Given this, cancer cell proliferation was assessed with cell 
counting and BrdU assay, and apoptosis was assessed by Caspase 3/7 Glo, PARP cleavage and 
TUNEL assays. The colony formation assay was used as a measure of cell stemness in CCSCs. 
Western blotting was used to determine protein levels associated with the β-catenin signaling. 
We first show that extracts from sweet sorghum dermal layer stimulated apoptosis and 
suppressed cellular proliferation in CCSCs and HCT116 cells, more so than the pith. 
Furthermore, the dermal’s activity was diminished, but not abrogated in p53 variants of colon 
cancer cells indicating partial p53-dependency. The dermal layer reduced cancer cell stemness 
by decreasing colony formation of CCSCs, indicating anticancer activities beyond suppressing 
proliferation and inducing apoptosis. Interestingly, the dermal layer had more 3-
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deoxyanthocyanidins than pith and this was associated with increased activity. These compounds 
are reported to have potent anticancer and phase II enzyme inducing activities8. Further 
investigations were carried out in the dermal layer, leaf and seed head to directly compare 
anticancer activities from these extracts. The molecular mechanisms for apoptosis were also 
investigated in the dermal layer and seed head, the most potent proapoptotic sweet sorghum 
components. Western blotting revealed that elevation in apoptosis was correlated with concurrent 
suppression of β-catenin (r = -0.920; P < 0.01), β-catenin’s down-stream prosurvival targets c-
Myc (r = -0.922; P < 0.01) and Survivin (r = -0.519; P < 0.01). Together, our data suggests that 
apoptosis was achieved via favorable modulation of aberrant β-catenin signaling. 
 For in vivo studies of inflammation and oxidative stress, the murine Western/high-fat diet 
(HFD; 40% kcal fat) induced obesity and oxidative stress model was utilized. Male and female 
A/J mice were provided with HFD and low-fat diet control (LFD) for 10 weeks with and without 
1% sweet sorghum stalk (dermal layer) extract (SS). During the treatment period, weekly 
measures of bodyweight, feed intake and water intake were collected. At the end of the study, 
dual energy X-ray absorptiometry (DEXA) was performed to assess adiposity. After treatment 
period, mice were sacrificed, vital organs weighed, and tissues and plasma collected for further 
analysis. The inflammatory markers NF-κB, tumor necrosis factor  (TNF), interleukin-6 (IL-
6) and IL-1β, the macrophage marker F4/80, and monocyte chemotactant protein-1 (MCP-1) 
were assessed in the colonic mucosa by qPCR. Barrier function of the colon was assessed by 
measuring the tight junction proteins, occludin and zona occluden-1 (ZO-1), by qPCR. Oxidative 
stress was assessed in the plasma by levels of 8-isoprostane (8IP). Feeding of SS extract in both 
LFD and HFD consuming groups did not negatively influence bodyweight, feed intake, water 
intake, and vital organ weights, indicating that SS extract was well-tolerated in male and female 
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A/J mice consuming HFD and LFD at 1% of diet. SS extract also reduced the systemic levels of 
oxidative stress as measured by plasma 8-isoprostane levels. SS extract did not improve 
adiposity in HFD consuming mice.  
 It was demonstrated that the stalk (pith and dermal layer), leaf, and seed head contain 
phenolic and antioxidant compounds conferring anticancer properties in colon cancer stem cells, 
supporting the hypothesis. This activity was most prominent in the dermal layer and seed head. 
Furthermore these extracts were shown to act via decreasing β-catenin and β-catenin’s 
prosurvival target genes. Additionally, we have demonstrated phenolic rich extract from dermal 
has in vivo antioxidant activities, and was well-tolerated in a high-fat diet mouse model of 
obesity and oxidative stress. More research is still needed to further elucidate the mechanisms 
through which sweet sorghum derived bioactive compounds favorably alter β-catenin levels in 
vitro and oxidative stress in vivo. Together this data suggests that sweet sorghum, an attractive 
source of fermentable sugars for biofuel production producing large quantities of biomass, is also 
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 Sorghum bicolor is the fifth most cultivated cereal crop worldwide1. Varieties of S 
bicolor, known as grain sorghum, are cultivated for human food and animal feed.  Other 
varieties, known as sweet sorghum, concentrate sugar in the pith cells of the stalk. As a 
consequence, sweet sorghums have thicker taller stalks with smaller seed heads12. Recently, 
interest has grown in the use of sweet sorghum as a feedstock for biofuel production due to 
reduced water requirements, shorter growing periods and reduced cultivation cost when 
compared to other feedstocks1. Furthermore, sweet sorghum can grow in marginal lands, and 
therefore does not have to compete with current food production, as is the case with corn and 
sugar cane1,13. Production of biofuel from sweet sorghum can be made more attractive when 
producers utilize the biorefinery approach14. In this approach, the entire above ground portion of 
the plant is utilized in the creation of energy and value-added products, minimizing waste, and 
thereby reducing the costs associated with the generation of biofuels15. Such products could 
include bioactive extracts prepared for the purposes of human health.  
 Biofuel production of sweet sorghum generates large masses of biological wastes 
comprised of stalks, leaves, leaf sheaths and immature seed heads2. Establishing biorefinery 
processes for sweet sorghum and other sources of biomass has been the center of recent 
investigations and reviews14–16. These publications have focused on: Creation of ethanol; 
Generation of steam power from combustion; Generation of butanol; Creation of fiber products 
and wood plastic composites; Production of nanomaterials; etc14,15. Recently, there has been an 
increasing interest in the use of biomass as a source of bioactive plant metabolites for human 
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health and other purposes17. These bioactive metabolites may include phenolics, carotenoids, 
glucosinolates and others depending on the source of bioactive compounds. Phenolics, a broad 
class of plant compounds that include one or multiple phenolic ring structures, are broadly 
spread throughout the plant kingdom18. It has been well reported that stalks, leafs and seed heads 
of sorghum contain phenolics4–7 with bioactivity15–17. However, most of the information pertains 
to grain sorghum varieties, not sweet sorghum varieties. In addition, these products, particularly 
the leaves and leaf sheaths, have been used by traditional healers in Africa and India for anemia, 
epilepsy, stomach ache, and interestingly, cancer3.  
 Recent evidence suggests that bioactive compounds (e.g. phenolic acids, flavonoids, 
stilbenoids, carotenoids) confer the protective and preventive effects against chronic diseases, 
such as cancer, associated with a plant-based diet19. Colorectal cancer is one such disease and is 
estimated to be the second most common cancer in females and third most common in males in 
the US20. Furthermore, it has been estimated that up to 80% of colorectal cancers are caused by 
diet and dietary factors19. This understanding has increased the demand for information 
regarding the role of dietary constituents in the prevention and treatment of diseases, such as 
colorectal cancers. In fact, there are multiple clinical trials investigating the preventive and 
therapeutic roles of curcumin, resveratrol, and n-3 polyunsaturated fatty acids for colon cancer21.   
 The process by which normal colonic epithelium progresses to colon cancer is multi-step, 
whereby cells accumulate successive genetic alterations, establish clones and gain a proliferative 
advantage22. The traditional pathway to colorectal cancer accounts for 70% to 85% of all cancers 
and starts with loss of APC function22, which results in accumulation of β-catenin and aberrant 
WNT/β-catenin signaling. This aberrant β-catenin signaling occurs in almost all cases and drives 
colorectal carcinogenesis23,24. Loss of APC is then followed by mutation of K-ras, loss of 18q, 
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and finally loss of p53 via 17p loss22. p53 is responsible for cell cycle arrest and apoptosis25. 
Therefore, it prevents the build-up of mutated genomes and the advancement of cancer. p53 is 
abnormal in 50% to 75% of all colorectal cancers, and this marks the transition from noninvasive 
to invasive disease22. Furthermore, loss of p53 disrupts normal tumor responses to conventional 
therapies, such as 5-Fluorouracil, thus making it difficult to treat these advanced tumors with 
conventional therapies26. Bioactive compounds are often found in complex mixtures in nature27, 
and, unlike a single therapeutic agent, contain the ability to influence multiple cellular pathways. 
Mixtures such as green tea extract and grape seed extract with resveratrol have demonstrated 
anticancer activity that act in both p53-dependent and p53-independent mechanisms, pointing to 
the ability of these mixtures to influence multiple pathways28,29. These findings warrant further 
investigations into uncovering natural sources of potential chemotherapeutic and 
chemopreventive agents. 
 Inflammation and inflammatory conditions of the bowels have been strongly linked to 
colon cancer30–32. In all patients with inflammatory bowel disease (IBD), 20% will develop what 
is known as colitis-associated cancers33. These cancers are a subset of colorectal cancers 
associated with IBD with a similar carcinogenesis to that of sporadic colorectal cancers33. Non-
colitis-associated colorectal cancers (i.e. sporadic colorectal cancer) have much in common with 
colitis-associated cancer, including increased inflammatory cytokine expression and immune cell 
infiltrates33. Inflammation promotes the production of reactive oxygen species, which cause 
DNA oxidative damage34, and this may be a source of somatic mutations promoting tumor 
progression. Furthermore, inflammatory signaling can be mitogenic, promoting the growth of 
pre-cancerous and cancerous cells34,35. Obesity is a condition associated with chronic 
inflammation and oxidative stress, and this may be important in the promotion of obesity-related 
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cancer36. The prevalence of obesity is high and it is estimated that 20% of cancer cases are 
attributable to obesity37,38. 
  Intriguingly, there many studies documenting the antiinflammatory and antioxidant 
properties of bioactive compounds. For example isothiocyanates and curcumin decreased NF-κB 
signaling39. Grapefruit bioactives suppressed COX-2 expression and colon carcinogenesis in an 
azoxymethane model of colorectal cancer40. Whole plant foods, such as berries, broccoli, and 
grape fruit, are reported to have beneficial properties for obesity-enhanced cancers36. Luteolin, a 
flavonoid found in S bicolor decreased COX-2 expression in a rodent model of skin cancer41. 
 Developing new and sustainable sources of bioactive compounds with therapeutic value 
will be important in the future treatment and prevention of chronic disease. Given the need for 
non-conventional therapies in the treatment of colorectal cancer, the prevalence of high-fat diet 
and obesity in the general public, and the general lack of information with respect to sweet 
sorghum bioactives, the anticancer properties of sweet sorghum were investigated in in vitro 
models of colorectal cancer, and the antiinflammatory and antioxidant properties in an in vivo 
murine model of high-fat diet induced obesity and colonic inflammation.  
1.2 Literature Review. 
1.2.1 The Sweet Sorghum Plant. 
 Placing fifth worldwide in cereal production1, Sorghum bicolor is a cereal of high genetic 
variability42, resulting in high morphological and phenotypic variation43. This variation results in 
varieties of Sorghum bicolor, called sweet sorghum, which concentrate simple sugars (glucose, 
fructose and sucrose12) in the pith cells of the stalk1,43. As a result of this sugar storage, sweet 
sorghum varieties typically have taller, thicker stalks and smaller seed heads12.  This can be seen 
in Figure 1. Given these unique characteristics, it is no surprise that sweet sorghums are used to 
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produce a myriad of products, including syrups, sugars, alcohol, paper, fencing, roofing, 
chewing, and forage12,16. Sweet sorghums, and other S. bicolor ssp., are C4 plants characterized 
by high photosynthetic efficiency, producing high quantities of biomass44. Biomass of sweet 
sorghum includes stalk (pith and dermal layer), leaves, leaf sheaths, and seed head.  
 
Figure 1.  A cross-section of sweet sorghum stalk and a crop of sweet sorghum. (Left) A cross-
section of a sorghum stalk illustrating the outer dermal layer and inner pith section. Adapted 
from45. A crop of grain sorghum next to a crop of sweet sorghum (Right). 
  
In recent decades, interest in the use of sweet sorghum as a feedstock for biofuel has 
increased16,46,47. Sweet sorghum is has been recommended as an alternative biofuel, as it can be 
advantageous to other feedstocks depending on location and grower’s needs (Table 1)1. Sweet 
sorghum has a shorter growing period of 4 months and can be harvested multiple times in one 
growing season1. Sweet sorghum can grow on marginal lands not used for food production48. 
Sweet sorghum also has reduced water requirements, reducing the cost of irrigation when 
compared to corn and cane sugar1. This is in contrast to corn ethanol, as the edible starches are 
converted to the fermentable sugars needed for ethanol production. Additionally, sorghum 
directly produces fermentable sugars, bypassing unnecessary enzymatic conversions of starch. 
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These characteristics result in a feedstock for biofuel production requiring less water and 
financial cost to produce1. This combination may prove sweet sorghum as an attractive 
alternative to other biofuel feedstocks. 
Table 1. Comparison of sweet sorghum biofuel production to other feedstocks. 
parameter sweet sorghum sugarcane maize 
crop duration (months) 4 12 4 
water needs (m3/ha) 4000 36000 8000 
grain yield (t/ha) 2.0 -- 3.5 
green stalk yield (t/ha) 35 75 45 
cultivation cost with irrigation ($/ha) 238 995 287 
total ethanol (L/ha) 3160 8925 3216 
ethanol cost ($/kL) 75.3 111.5 89.2 
Adapted from and further reviewed in1. 
 
 The biorefinery approach to biofuel production is a concept, which mimics the traditional 
oil refinery, makes use of the entire above ground portion of the plant to produce energy and 
high value products, reducing the cost of biofuel production15. With respect to sweet sorghum, 
investigations into applying the biorefinery approach to sweet sorghum have focused on: 1) The 
creation of ethanol; 2) The generation of steam power from combustion; 3) generation of 
butanol; and 4) creation of fiber products and wood plastic composites14,15.  Figure 2 illustrates 
one such example from14. Recently, there has been an increasing interest in the use of plant 
secondary metabolites, which have inherent health benefits, as valuable biofuel co-products17. 
For example, phenolics are a broad class of plant secondary compounds that include a single or 
multiple phenolic ring structures, and are found throughout the plant kingdom18. Furthermore,  
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these phenolics compounds have been reported to be present in various sources of sorghum 
biomass (stalk, leaves, leaf sheaths, grain, glume, etc).
 
Figure 2. A schematic drawing of the biorefining sweet sorghum stalk. Adapted from14.  
 In a process developed by Great Valley Energy LLC, the stalk of sweet sorghum is cut 
into approximately 30 cm segments, called billets. These billets are further processed into sugary 
pith cells from the dermal layer as illustrated in Figure 3. The simple fermentable sugars are then 
separated from the pith cells and are fermented into ethanol. This leaves large amounts of dermal 
layer from the stalk of sweet sorghum, which has been proposed to be used for creating wax 
products, pulp, paper, and other products (Figure 4). Currently, there is relatively little known 
with respect to the in vitro and in vivo bioactive compounds and bioactivity properties of the 
stalk of sweet sorghum. Given the unique opportunity for this important component to serve as a 
source of bioactive compounds for human health, more research is needed to assess these aspects 








Figure 4. Proposed uses for sorghum stalk by Great Valley Energy, LLC. 
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1.2.2 Sorghum Phenolics and Bioactivity. 
 Phenolics represents a broad class of compounds containing one or more aromatic ring 
structures with one or more hydroxyl substitutions18. Sorghum bicolor contains phenolic 
compounds with antioxidant activity, which confer protective effects to the sorghum plant49. 
When consumed by humans, these same phenolic compounds confer health benefits, referred to 
here as bioactivity50. Phenolic compounds have the ability to reduce free radicals, quenching free 
radical species and terminating free radical chain reactions, which can promote, among many 
things, damage of genomic DNA18,51. Total phenolics (TP) and antioxidant activity (AOA) can 
therefore be measured in a phenolic rich extract by the ability of the extract to reduce a substance 
by donating protons or electrons.  
 The Folin-Ciocalteu assay is used to assess the level of TP. It is based on the ability of a 
source of phenolics to participate in a hydrogen atom transfer to reduce the Folin-Ciocalteu 
reagent comprised of phosphomolybdate and phosphotungstate creating a blue color with a 
maximum absorbance at 765 nm52. Gallic acid is by far the most common standard phenolic 
compound used for quantification purposes in the Folin-Ciocalteu assay. The 2,2-diphenyl-1-
picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) are 
stable free radical pigments, which are reduced in the presence of antioxidants to form a 
colorless product53. The disappearance of free radical can therefore be measured by a 
spectrophotometer. Assays based on the quantification of the disappearance of the free radical 
species can quantify the AOA of an unknown to that of a standard solution. Trolox is most 
commonly used in these assays for the quantification of antioxidant activity. The oxygen radical 
absorbance capacity (ORAC) assay is another method for measuring AOA of a substance. It is 
based on the ability of a substance to prevent the oxidative degeneration of a fluorescent 
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molecule, typically fluorescein. Like DPPH and ABTS, Trolox is used as a standard antioxidant 
and used for quantification purposes.  
 Table 2 summarizes previous efforts to quantify TP and AOA from different components 
of S. bicolor separated by the type of sorghum used in the study. The levels of TP and AOA in 
sorghum range widely and depend on the component of sorghum extracted, as well as genotype. 
The grain has been the most studied with respect to TP and AOA. TP and AOA values have been 
reported to range from 2 to 9 mg GAE/g (Folin-Ciocalteu assay)54 and from 5 to 85 µmol TE/g 
(DPPH assay)6,55 in the grain of grain sorghum, respectively.  The grain of dye sorghum contains 
much higher TP and AOA with reported values as high as 23 mg GAE/g and 147 µmol TE/g 
(DPPH), respectively. The presence of concentrated polyphenolic pigments, known as 
anthocyanins, may be responsible for these observations, as they can contribute to TP and AOA. 
Furthermore, antioxidants seem to be more concentrated in the bran, which makes up the hard 
outer layer of the grain, containing up to 782 µmol TE/g (ABTS)6. Other parts of the sorghum 
plant, including the leaves and stalk of sorghum have been reported to contain 11.7 and 1.0 mg 
GAE/g of total phenolics, respectively56. The leaf sheaths of dye sorghum have been reported to 
contain as much as 135 mg GAE/g4. This is also due to the presence of anthocyanins, which are 
concentrated in the leaf sheaths of these varieties of sorghums. These data reflect the high 
variation of TP and AOA inherent in the different varieties and components of sorghum, which 
may affect related bioactivities.  
 Phenolic acids represent the simplest phenolic compounds, containing a single aromatic 
ring with hydroxyl and methoxyl substituted groups, and are derivatives of cinnamic acid and 
hydroxybenzoic acid49. They are spread broadly throughout the plant kingdom and estimated to 
contribute to one third of the total phenolic compounds consumed in the diet57. The major  
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Table 2. Comparisons of reported Sorghum bicolor total phenolic and antioxidant activity. 
sorghum source method contenta 


















10-170 µmol TE/g54 
125-562 µmol TE/g55 
5-85 µmol TE/g54 
15-43 µmol TE/g55 
2-9 mg GAE/g54 
8-30 mg GAE/g55 
81-236 µmol TE/g55 
3.4-11.7 mg GAE/g56 
0.4-1.0 mg GAE/g56 










83-147 µmol TE/g5 
9-23 mg GAE/g5 
10.6-17.5 mg TAE/g58 
3760-5580 µmol TE/g DM4 
65-135 mg GAE/g4 







28-786 µmol TE/g6 
21-716 µmol TE/g6 
6-226 µmol TE/g6 
6-202 µmol TE/g6 
aSuperscripted numbers indicate references. DM = dry matter; TE = Trolox equivalents; GAE = gallic acid 
equivalents. 
  
phenolic acids identified in sorghum grain include protocatechuic, gentisic, caffeic, cinnamic, 
ferulic, sinapic, salicylic and p-coumaric59 and are illustrated in Figure 5. Vanillic, p-
hyrdroxybenzoic and gallic acids have also been identified in the grain of sorghum5. p-coumaric, 
o-coumaric, and p-hydroxybenzoic acids have been identified in the leaf sheaths of sorghum 
varieties4. In the leaves, p-hydroxybenzoic, o-coumaric, p-coumaric, caffeic, ferulic, and gentisic 
acids have been reported to inhibit Locusta migratoria feeding60, indicating the importance of 
these compounds to plant defense. p-coumaric and ferulic acids have been reported in the stalks 
of sorghum44. Table 3 summarizes efforts to identify and quantify phenolic acids and illustrates 
the variability in expression of these compounds in the parts of the sorghum plant. For example, 




Figure 5. Phenolic acids identified in Sorghum bicolor. Adapted from61. 
Table 3. Reported phenolic acids in Sorghum bicolor. 
class compound source concentrationa 
phenolic acids protocatechuic acid grain 7-141 mg/kg5 
p-hydroxybenzoic acid grain 15-34 mg/kg5 
 leaf reported60 
vanillic acid grain 8-51 mg/kg5 
 leaf reported60 




 leaf reported60 
 pith 13907 g/kg CWR44 
 bark 19893 g/kg CWR44 
o-coumaric acid leaf reported60 
ferulic acid grain 105-343 mg/kg5 
 leaf reported60 
 pith  6466 g/kg CWR(b)44 
 bark 8446 g/kg CWR(b)44 
gallic acid grain 20-46 mg/kg5 
gentisic leaf reported60 
caffeic acid grain 26-52 mg/kg5 
cinnamic acid grain 5-20 mg/kg5 
hydroxybenzoic acid leaf sheath 381-1555 mg/kg4 
salicylic grain reported59 
syringic grain reported59 
sinapic grain reported59 
aSuperscripted numbers indicate references. Reported, references which only reported presence of compound. 




 The bioactivity of phenolic acids in cancer cells have been well reported and are 
summarized here in Table 4. Phenolic acids are able to alter many steps of the carcinogenesis 
process. DNA damage as a result of oxidative damage contributes the formation of somatic 
mutations which contribute to carcinogenesis51. Certain phenolic acids, such as ferulic and 
cinnamic acid, have been shown to inhibit the promotion stage of cancer by decreasing DNA 
damage62. This is further supported by cinnamic acid’s effect on increasing glutathione S 
transferase activity63, an important enzyme in antioxidant defense, which helps in decreasing 
oxidative stress63. Hyper-proliferation and protection from apoptosis are important hallmarks to 
cancer64. Phenolic acids such as p-coumaric acid62 and vanillic acid65 have been shown to 
decrease proliferation and increase apoptosis in a number of cancer cell lines, including colon 
cancer cells. COX-2 contributes to inflammation, proliferation, and reduced apoptosis and 
Inhibitors of COX-2 activity have long been associated with decreased rates colorectal cancer66. 
Ferulic acid was demonstrated to reduce colon cancer HT29 cell proliferation through altering 
COX-262.  Interestingly, these phenolic acids have been identified in the grain, leaf, leaf sheath 
and stalk of sorghum varieties. 
Table 4. Bioactivity of phenolic acid compounds identified in Sorghum bicolor. 
class compound model  biological activitya 
phenolic 
acids 
protocatechuic acid HepG2 liver cancer cells 
 
T47D breast cancer cells 
↑ apoptosis through JNK & p38 stimulation67 
↓ proliferation; ↑ apoptosis68 
vanillic acid HT-29 colon cancer cells 
NIH/3T3 
↓ proliferation; ↑apoptosis65 
↓ proliferation; ↑apoptosis65 
p-coumaric acid HT-29 colon cancer cells 
EMT-6 breast cancer cells 
SW-620 colon cancer cells 
LOVO colon cancer cells 






ferulic acid HT-29 colon cancer cells 
 
T47D breast cancer cells 
↓proliferation; ↓ genotoxicity;  
↓ COX-262 
↓ proliferation; ↑ apoptosis68 
caffeic acid T47D breast cancer cells ↓ proliferation; ↑ apoptosis68 
cinnamic acid F344 rats colonic mucosa ↓ genotoxicity; ↑ glutathione-S-transferase63 
aSuperscripted numbers indicate references. 
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 Flavonoids are the second major class of sorghum phenolics (Figure 6) and represent the 
largest class of phenolics in the plant kingdom, and can be divided into six major subclasses 
based on C-ring substitutions; flavanones, flavonols, flavones, catechins, anthocyanidins, and 
isoflavones69. Table 5 summarizes previous efforts to identify and quantify sorghum flavonoids. 
In sorghum, anthocyanidins, flavones, flavanones, and flavonols have been previously identified. 
The anthocyanidins apigeninidin and luteolinidin, and their methoxylated counterparts, 7-
methoxyapigeninidin and 5-methoxyluteolinidin, are seemingly ubiquitous in the sorghum plant 
and have been identified in sorghum glume, grain, leaf and leaf sheath5,70. These compounds lack 
a hydroxyl group on the 3-carbon and are collectively known as 3-deoxyanthocyanidins. When 
compared to their 3-hydroxylated counterparts, these compounds are more stable in acidic 
solutions and have been shown to be more cytotoxic to cancer cells4,71. These compounds also 
induce detoxifying phase II enzymes8. Sorghum is the only plant known to contain significant 
quantities of these 3-deoxyanthocyanidins suggesting it to be a unique reservoir of health 
benefiting compounds4. 
 Apigenin, luteolin, and tricin are flavones identified in the grain and the stem of 
sorghum5,7,72. Apigenin has demonstrated anticancer activity in HeLa cells and Hep3B cells11,73, 
and luteolin has demonstrated anticancer activity in vitro and in vivo41. While certain flavonoids 
are seemingly ubiquitous throughout the sorghum plant, the flavanones naringenin and 
eriodictyol have only been identified in the grain of sorghum74 and is currently unknown if it is 
expressed in measurable quantities in other parts of the sorghum plant. Naringenin decreases 
tumor growth in ddY mice implanted with S-180 sarcoma cells9, and Eriodictyol inhibits EGF 
induced JB6 Cl41 cell transformation in vitro75. Kaempferol 3-rutinoside-7-glucuronide76, 
taxifolin and related glycosides77, quercetin glycosides7, catechins78, epicatecin78 and 
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procyanidins78 have also been reported in sorghum grain and each demonstrating unique 
anticancer properties.  
 
Figure 6. Common flavonoids identified in Sorghum bicolor. Adapted from49. 
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Table 5. Reported flavonoids in Sorghum bicolor. 
class compound source concentrationa 
































malvidin leaf sheath 570-1030 mg/kg4 








tricin stem reported7 
flavanones naringenin grain 5.6-48.4 mg/kg74 
eriodictyol grain 5.6-12.9 mg/kg74 
eriodictyol 5-glucoside grain reported79 
flavonols kaempferol 3-rutinoside-7-
glucuronide 







Dihydroflavonolsb taxifolin grain reported77 
taxifolin 7-glucoside grain reported77 
flavan-3-olsb catechin grain 10-180 mg/kg78 
epicatechin  grain 10-180 mg/kg78 
procyanidins grain 1300 – 22000 mg/kg78 
stilbenes trans-resveratrol grain reported5 
trans-piceid grain reported5 
aSuperscripted numbers indicate references. Reported, references which only reported presence of compound. 
bSub-class of flavonols. 
  
 Echoing the wide range in TP and AOA, flavonoid content is highly variable and ranges 
widely depending on part of the plant under investigation. For example, there is a 45-fold 
difference in the highest reported levels of apigeninidin in the grain and leaf sheath of sorghum. 
Therefore, the large variation in quantity and composition of phenolics from these different parts 
of the sorghum plant is expected to create a large variation in the bioactivity associated with the 
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phenolics from each part of the plant. This warrants further investigations into the bioactivity of 
the different parts of the sorghum plant in relation to their bioactive content. 
 Apart from phenolic acids and flavonoids, other phenolic compounds have been reported 
in sorghum grain. The stilbenoids piceid and resveratrol have been reported in the grain of red 
sorghum5. These compounds are known contain high antioxidant activity and have demonstrated 
strong bioactivities in many studies. For example, resveratrol decreased the number of high 
multiplicity aberrant crypt foci, a biomarker for colorectal cancer, in rats80. Additionally, 
resveratrol induced apoptosis in the HCT116 colon cancer cell line81.  
Table 6. Bioactivity of flavonoid compounds identified in Sorghum bicolor. 




sorghum extract  
Hepa 1c1c7 
HT-29 colon cancer cells 
↑ phase II enzymes8 
↓ proliferation8 
luteolinidin HL-60; HepG2 ↓ proliferation10 
apigeninidin HL-60 leukemia cells ↑ apoptosis; ↑Bak; ↑Bax82 
flavones apigenin Hep3B liver cancer cells 
HeLa cervical cancer cells 
↓ VEGF expression11; 
G1 cell cycle arrest; ↑ apoptosis73 
luteolin JB6 P+ mouse epidermal cells 
 
SKH-1 hairless mouse  
↓ Nf-κB, ↓ Src kinase, ↓ PKCε, 
↓ COX-241 
↓ UVB induced skin cancer41 
flavanones naringenin ddY mice implanted with S-180 
Sarcoma 
↓ tumor growth9 
eriodictyol JB6 Cl41 cells ↓ RSK2; ↓ EGF-induced cell 
transformation75 
flavonols kaempferol  A549 lung cancer cells ↓ proliferation; ↑ apoptosis via MEK-
MAPK83 
quercetin  HCC1937 breast cancer cells ↓ proliferation; ↓ PI3K-Akt/PKB 
pathway84 
 taxifolin HCT116 colon cancer cells ↑ detoxifying enzymes by activating 
antioxidant response element85 
flavan-3-ols catechin PANC-1 pancreatic cancer cells 
MIAPACA pancreatic cancer cells 
↑ apoptosis86 
↑ apoptosis86 
stilbenes trans-resveratrol F344 rats 
C57BL/6NIA mice 
HCT116 colon cancer cells 
↓ HMACF80 
↓ IGF-1; ↓ insulin87 
↑ apoptosis; ↑ caspases 2,9,8, & 381 
aSuperscripted numbers indicate references. 
 
 Collectively, this data demonstrates that the sorghum plant contains a wide variety of 
phenolic compounds including phenolic acids, a myriad of flavonoids and stilbenoids. These 
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compounds are widely distributed throughout the plant with a wide range in content, which is 
dependent on the component and variety under investigation. These compounds, in isolation and 
as part of complex bioactive extracts, have demonstrated anticancer and antiinflammatory 
bioactivities in multiple in vitro and in vivo models. 
1.2.3 Anticancer Mechanisms of Bioactive Compounds 
 There is a growing literature reporting the anticancer activity associated with sweet 
sorghum and related bioactive compounds. For example 3-deoxyanthocyanidin rich extracts 
were reported to induce phase II detoxifying enzymes4, apigeninidin and luteolinidin suppressed 
proliferation10, and yet other compounds induced apoptosis or favorably altered some host genes 
to elicit health-promoting responses, disfavoring cancer survival. There are multiple review 
articles in the literature addressing this enigma related to anticancer mechanisms of bioactive 
compounds. Although it would be out of the scope of this literature review to go in depth into all 
known altered pathways related to the effects of bioactive compounds on inflammation, 
proliferation, apoptosis, angiogenesis, metastasis, etc., it warrants sufficient discussion on the 
topic of the fundamental molecular mechanisms of bioactive compounds responsible for the 
multiplicity of observed effects they elicit. 
 Reactive oxygen species (ROS), such as oxygen radicals (e.g. superoxide) or non-radical 
oxygen compounds (e.g. hydrogen peroxide), which are easily converted into radicals, are highly 
reactive and promote oxidative stress88,89.  ROS and other reactive species are a natural 
consequence of aerobic metabolism and are typically buffered by inherent enzymatic and non-
enzymatic cellular antioxidant systems (e.g. antioxidant vitamins, catalase, superoxide 
dismutase, etc)90. When natural oxidative stress defenses are overwhelmed, reactive species can 
damage the DNA, proteins and lipids implicated in many chronic disease states89,90. This is 
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collectively referred to as oxidative stress. Oxidative stress is directly involved in the initiation, 
promotion and progression stages of carcinogenesis through direct DNA damage, altered gene 
expression and signaling pathways88. In this way, bioactive compounds, acting as direct 
antioxidants, can interfere with all three of these steps in carcinogenesis.  Furthermore, oxidative 
stress incites inflammatory processes through activating proinflammatory transcription factors 
(e.g. NF-κB, AP-1, HIF-1α, PPAR-γ, Nrf2, etc)88. This altered inflammatory/oxidative stress axis 
also promotes cancer through increasing radio-resistance, chemo-resistance, cellular 
proliferation, angiogenesis, and metastasis, and by decreasing apoptosis88. Intriguingly, bioactive 
compounds have demonstrated numerous antiinflammatory responses involving multiple 
pathways. For example, resveratrol was shown to decrease lipopolysaccharide induced NF-κB 
activation in colorectal cancer cells91. Apigenin has been reported to inhibit NF-κB, COX-2, 
VEGF, and HIF1α34. Grapefruit bioactive compounds were shown to inhibit iNOS and COX-2 
expression in the rodent azoxymethane-induced colorectal cancer model40. 
 Oxidative stress is also associated with key cancer-related pathways regulating cellular 
proliferation, apoptosis and metastasis. Generation of ROS is often observed in cells undergoing 
apoptosis caused by anticancer agents and may be a common mediator of apoptosis across a 
wide range of proapoptotic agents92. Oxidative damage can act as a direct trigger of apoptosis 
and cell cycle arrest by damaging DNA and stabilizing p5392. This can induce cell cycle arrest 
through p53 induced p21 expression, and subsequently apoptosis when DNA is beyond repair92. 
Beyond DNA damage, ROS has been shown to regulate major cell signaling pathways including 
MAPK pathway, which lead to the activation of redox sensitive transcription factors NF-κB and 
activator protein-193. Furthermore, oxidative stress directly alters and inhibits the phosphatase 
catalytic site of PTEN, causing an increase in IP3 levels and thus promotes Akt signaling94. 
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Interestingly, there are many examples in the literature of bioactive compounds influencing 
redox sensitive cancer pathways. For example, quercetin inhibited breast cancer cell proliferation 
through suppressed Akt in cells with and without PTEN knockout84. Resveratrol and mulberry 
fruit induced apoptosis in a HT-29 and A172 cancer cells via ROS-dependent mitochondria 
pathways, respectively95,96. Curcumin caused G2/M cycle arrest and apoptosis in lung cancer 
cells due to in part by DNA damage inducing p53 stabilization97. 
 Ironically, the anticancer activity of bioactive compounds hinge on this balance between 
ROS and antioxidant defense. For example, quercetin, at lower concentrations (1-40 µM) may 
prevent cancer initiation by acting directly as an antioxidant neutralizing ROS and other radicals 
and inhibiting DNA damage98. However, after tumor formation quercetin and similar compounds 
continue to have beneficial effects at higher concentrations (>40 µM for quercetin)98. At these 
concentrations, bioactive compounds, such as quercetin, elevate ROS to levels that signal 
apoptotic responses via DNA damage stabilization of p5398. However, many cancers circumvent 
this protective mechanism by inactivating p5322,99. This might imply that quercetin and similar 
compounds are unsafe to non-cancerous cells at such levels. However, numerous accounts report 
that bioactive compounds are selective and generally induce cytotoxic effects only in cancerous 
cells100–103. This is disquieting nonetheless, as it would be easy to imagine scenarios where such 
mechanisms might fail. For example, the generation of excess ROS in normal cells would 
contribute to genetic mutations. Alternatively bioactives, by acting as an antioxidant in cancerous 
cells to suppress ROS, would prevent the induction of important tumor suppressors, such as p53. 
This may be the case as to why clinical trials utilizing single bioactive agents fail to produce 
consistent results27,104. Furthermore, it was recently shown that single antioxidant compounds 
accelerated lung cancer progression via ROS-p53 axis disruption, supporting this notion105.  
21 
 
 Given this dichotomy of antioxidant/prooxidant and tumor-promoting/tumor-initiating 
responses, it may be that another main influence of bioactive compounds are through additional 
molecular mechanisms responsible for their preventive and protective effects. In addition to 
prooxidant and antioxidant mechanisms of individual or multiple compounds, recent evidence 
suggests that multiple compounds act synergistically/additively to directly interact with proteins 
of interest, altering cellular responses. For example, resveratrol was shown to directly inhibit 
COX-2 in cell and non-cell based assays106. Quercetin and myrecitin were shown to dock with 
the opening of allosteric inhibitory pocket of MEK1107. In fact, quercetin was shown to out-
perform the MEK1 inhibitor PD098059107. Ultraviolet B light (UVB) promotes skin cancer 
partly by inducing COX-2 expression through Fyn kinase108. Caffeic acid was reported to inhibit 
UVB-induced skin carcinogenesis by direct inhibiting Fyn kinase activity108.  
These and similar studies point to anticancer mechanisms by which bioactive compounds 
directly modulate cell signaling pathways through physical interactions with proteins. This may 
partly explain why simple changes to biochemical structures (hydroxylation, methylation, etc) 
have been reported to alter the bioactivity of structurally related compounds. For example, B-
ring substation patterns were shown to change depending on location and number of hydroxyl 
and methoxyl groups109. If direct interaction with proteins is a major anticancer mechanism of 
bioactive compounds, then it is conceivable that these compounds can influence, to some degree, 
every aspect of the Hallmarks of Cancer as described by Hanahan and Weinberg64 through 
interactions with cell signaling circuitry, transcription factors controlling gene expression, 
cellular metabolism, as well as replication, transduction, and translation machinery. It may also 
explain, why in many cases single compounds do not elicit response in the complex 
heterogeneous tumor environment, as multiple pathways related to apoptosis, cell cycle, 
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inflammation, metabolism, etc. are unfavorably altered and would require multiple compounds 
disrupting multiple pathways to elicit an anticancer effect observable at a phenotypic level.  
When taken together, the evidence presented points to a highly complex and 
sophisticated means by which multiple bioactive compounds elicit anticancer responses. 
Furthermore, these responses may not be mutually exclusive and depend on the presence of 
multiple compounds (similar to what is found in fruits and vegetables) before the full scope of 
anticancer effects are observed. These effects are multi-layered and most probably involve 
multiple mechanisms, including antioxidant effects, prooxidant effects, antiinflammatory effects, 
direct protein interactions, and other yet defined mechanisms. 
1.2.4  Colorectal Cancer and Natural Chemoprevention and Chemotherapy. 
1.2.4.1 The Colon and Colorectal Cancer. 
 The colon is the terminal segment of the gastrointestinal tract, measuring 1.0 to 1.5 m in 
length110. Depicted in Figure 7, the colon starts at the cecum, following the periphery of the 
peritoneal cavity ending at the rectum, which extends into the pelvis terminating at the anal 
canal110. The colon can be divided into left and right colon and further subdivided into ascending 
colon forming the right colon, and the transverse and descending colon, which together forms the 
left colon110. The basic functions of the colon are to transport digested matter, absorb water, 
minerals and some vitamins, and provide conditions for bacterial fermentation110. When 
observing a cross section of the colon, one sees the serosa, the circular and longitudinal muscle 
layers, the submucosa, the muscularis mucosae, and the mucosa111. The latter is formed by 
lamina propria, which contains ~80% of the antibody secreting cells of the body, and the crypts 
of the colon, which is lined by colonic epithelial cells110. 
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 At the base of the colon crypt (depicted in Figure 8) lies a population of 4 - 6 stem 
cells112. Upon signal, the colon stem cell, residing at the base of the crypt, divides 
asymmetrically, giving rise to one progenitor cell and one stem cell112. The progenitor cell moves 
up the crypt toward the lumen of the colon and continues to divide for the next one third of the 
crypt, called the proliferation zone113. The progenitor cell then differentiates in the final one third 
of the crypt and is sloughed off into the lumen every 4-5 d112.  
 
 




Figure 8. Organization of the colon crypt. Adapted from113. 
 Colorectal cancer is estimated to be the second most common cancer in females and third 
most common in males in the US20. Worldwide colorectal cancers impact one million people 
every year, resulting in over half a million cancer deaths114. Numerous epidemiological studies 
indicate an increase in the consumption of fruits and vegetables quantity and variety is associated 
with decreased incidence of cancer, cardiovascular disease, and stroke115–118. In accordance with 
this, it has been estimated that 80% of colorectal cancers can be attributed to dietary factors19. To 
understand the role between diet and colorectal cancer it is important to have a greater 
understanding of the carcinogenesis of cancer.  
 The process by which normal colonic epithelium progresses to colon cancer is multi-step, 
whereby cells accumulate successive genetic alterations, establish clones and gain a proliferative 
advantage22. The traditional pathway to colorectal cancer accounts for 70% to 85% of all cancers 
and starts with loss of APC function22, which results in accumulation of β-catenin and aberrant 
WNT/β-catenin. This aberrant β-catenin signaling occurs in almost all cases and drives colorectal 
carcinogenesis23,24. Loss of APC is then followed by mutation of K-ras, loss of 18q, and finally 
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loss of p53 via 17p loss22. p53 is responsible for cell cycle arrest and apoptosis25. Therefore, it 
prevents the build-up of mutated genomes and the advancement of cancer. p53 is abnormal in 
50% to 75% of all colorectal cancers, and this marks the transition from noninvasive to invasive 
disease22. Furthermore, loss of p53 disrupts normal tumor responses to conventional therapies, 
such as 5-Fluorouracil (5-FU), thus making it difficult to treat these advanced tumors with 
conventional therapies26. 5-FU induces p53 expression through inhibiting thymidylate synthase 
(TS) leading to decreased incorporation of TS metabolites into DNA and RNA26. This causes 
damage that, among other responses, causes apoptosis induced partly by p5326. In this regard, 5-
FU acts analogously to the prooxidant anticancer mechanism of bioactive compounds. However, 
bioactive compounds are often found in complex mixtures in nature27, and, unlike a single 
therapeutic agent, contain the ability to influence multiple cellular pathways. Mixtures such as 
green tea extract and grape seed extract with resveratrol have demonstrated anticancer activity 
that act in both p53-dependent and p53-independent mechanisms pointing, to the ability of these 
mixtures to influence multiple pathways28,29. These findings warrant further investigations into 
uncovering natural sources of potential chemotherapeutic and chemopreventive agents. 
1.2.4.2 Colorectal Cancer and the Stem Cell Hypothesis. 
Embryonic stem cells are cells of the inner cell mass of the blastocyte, an embryonic 
structure formed during early stages of embryogenesis119. Embryonic stem cells are defined by 
their ability for self-renewal and their ability to differentiate into any cell lineage, including adult 
stem cells, a feature known as totipotency or pluripotency120. Adult stem cells have limited 
differentiation power (multipotency), and these cells differentiate into cells of their respective 
organs120. These cells occur in numerous somatic tissues including liver, blood, brain, colon, 
mammary, etc. (Figure 9)121. Adult stem cells are spread throughout the body in small numbers 
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and are typically maintained in a specialized region called the stem cell niche (Figure 10)122. 
Niches are composed of specialized cells that provide an anchor, secrete regulator signals, and 
control the proliferative behavior of adult stem cells122.  
 
Figure 9. Examples of stem cells found in adult somatic tissues. Adapted from121. 
 
Figure 10. Stem cell niches in normal and cancerous conditions. Adapted from122. 
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Increased understanding in the biology of stem cells has influenced our understanding 
tumorigenesis121. The cancer stem cell theory suggests that at the heart of most tumors exist a 
small number of cancer stem cells that drive the proliferation, renewal, and metastasis of 
cancers121,122. Cancer stem cells are aberrant forms of stem cells that are characterized the ability 
to develop into any cell in the overall tumor population due to self-renewal, symmetric and 
asymmetric division, multipotency, and the proliferative ability to drive continued expansion of 
the population of malignant cells121. Interestingly, these are characteristics shared with normal 
stem cells121. However, in cancer, the stem cell has acquired mutations that allow for malignant 
growth that is independent of the stem cell niche (Figure 10), highlighting the importance of 
niche-related regulation of proliferation and differentiation122.  
Wnt refers to wingless, a term coined in its discovery in drosophila development123. Wnt 
signals bind to G-protein coupled receptors (Frizzled) and result in disruption of a multi-protein 
complex containing APC, Axin, GSK-3β and β-catenin124. Normally, APC facilitates the binding 
of GSK-3β to β-catenin, resulting in the phosphorylation and degradation of β-catenin124. Wnt 
signals therefore disrupt this complex allowing for the accumulation of cytosolic β-catenin, and 
subsequent translocation to the nucleus124. Here it associates with members of the TCF/LEF 
family of transcription factors thus activating specific Wnt targets125. Under physiological 
conditions, this signaling pathway plays a critical role in regulating stem cell and crypt 
homeostasis125. As previously mentioned, loss of APC is an early event in colorectal cancer and 
results in similar transactivation of Wnt targets. Furthermore, established colorectal cancers 
depend on Wnt signaling125. However, colorectal cancers with established APC mutations show 




 Interestingly, bioactive compounds have shown efficacy in positively altering Wnt 
signaling in cancer cells. For example, genistein, an isoflavones found in soy, was shown to 
inhibit Wnt signaling through increased expression of GSK-3β126. Genistein treatment increased 
binding of β-catenin to GSK-3β, resulting in its subsequent phosphorylation and degradation126. 
Curcumin, a bioactive compound found in turmeric, inhibited Wnt signals resulting in decreased 
breast tumorosphere formation126. Curcumin has also diminished β-catenin signaling in HCT116 
cells126. These and similar findings point to a larger role of dietary bioactive compounds in the 
prevention and treatment of colon cancer, and the lack of dietary bioactive compounds is 
possibly a major reason for the high percentage of colorectal cancers attributed to diet.  
1.2.4.3 Inflammation and Colorectal Cancer. 
 Although incidence and mortality is high, evidence suggests that a majority of colorectal 
cancers are promoted by lifestyle factors127. Obesity, a known risk factor for colorectal cancer 
and lifestyle-related condition, is characterized by elevated systemic levels of insulin and 
inflammation, which may act in concert to accelerate colorectal carcinogenesis36,127. Increased 
adiposity causes chronic systemic inflammation as a result from the recruitment of macrophages 
into the adipose tissue and decreased secretion of the antiinflammatory adipokine adiponectin127. 
Decreased levels of adiponectin results in a decrease in the expression of tumor suppressors like 
p53, and an increase in the levels of proinflammatory cytokines, which increases the levels of 
ROS, which induces the AMP-activated protein kinase signaling pathway127.  
 Inflammation and inflammatory conditions of the bowels have been strongly linked to 
colon cancer30–32. In all patients with inflammatory bowel disease (IBD), 20% will develop what 
is known as colitis-associated colorectal cancers33. These cancers are a subset of colorectal 
cancers associated with IBD with a similar carcinogenesis to that of sporadic colorectal 
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cancers33. Colorectal cancers not associated with IBD have increased inflammatory cytokine 
expression and immune cell infiltrates33. Inflammation promotes the production of reactive 
oxygen species, which cause DNA oxidative damage34, and this may be a source of somatic 
mutations promoting tumor progression. Furthermore, inflammatory signaling can be mitogenic, 
promoting the growth of pre-cancerous and cancerous cells34,35. Obesity is a condition associated 
with chronic inflammation and this may be important in the promotion of cancer. The prevalence 
of obesity is high and it is estimated that 20% of cancer cases are attributable to this chronic 
disease state37,38. 
 The use rodent models of high-fat diet induced obesity have been reported in numerous 
studies investigating metabolic disorders associated with obesity. These studies have revealed a 
predictable progression of metabolic disease, which starts with changes in gut microbiota, 
increased intestinal permeability, and metabolic endotoxemia128. Feeding a high-fat diet to mice 
has been revealed to increase lipopolysaccharide containing microbiota and serum LPS 
concentrations128. HFD feeding has also been shown to increase intestinal inflammation and 
promotes oxidative stress through increased TLR-4 signaling and NF-κB activation129,130. HFD 
was also associated with increases in colonic IL-6, an inflammatory cytokine, and this was 
associated with increases in the development of pre-cancerous lesions in azoxymethane injected 
mice131. Oxidative stress can cause genomic damage resulting in somatic mutations and this can 
contribute to carcinogenesis. It has been shown that bioactive compounds can attenuate high-fat 
diet induced inflammation, oxidative stress and colon carcinogenesis. For example, red wine 
polyphenols were shown to decrease DNA oxidative damage in animals fed high-fat diet130. 
Furthermore, this study investigated carcinogen-induced colon cancer in mice fed a high-fat diet 
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and reported a decrease in colon tumor formation and changes in inflammatory gene 
expression130.  
 There are many studies documenting the antiinflammatory properties of bioactive 
compounds. For example isothiocyanates and curcumin decreased NF-κB signaling39. Grapefruit 
bioactives suppressed COX-2 expression and colon carcinogenesis in an azoxymethane model of 
colorectal cancer40. Whole plant foods, such as berries, broccoli, and grape fruit, are reported to 
have beneficial properties for obesity-enhanced cancers (reviewed in36). These and similar 
findings suggests a protective antiinflammatory role for dietary bioactive compounds.  
1.3 Summary. 
It is now understood that cancer is a heterogeneous disease characterized by mutations of 
normal genes causing uncontrolled cell growth. Cancer stem cells are aberrant forms of normal 
adult stem cells120. Understanding the role of stem cells in carcinogenesis is providing new 
insights and opportunities in the targeted treatment and prevention of colon cancer120,132,133. 
Indeed, several studies investigating targeted removal of cancer stem cells through molecular 
targets have yielded promising results134–138. Recent research into the role of bioactive 
compounds in targeting this elite class of cancer cell is promising133.  
Research into the bioactive constituents of foods has revealed that plants contain a 
plethora of secondary metabolites. There are over 100,000 bioactive compounds in plants and are 
broadly classified by structure (e.g. phenolics, carotenoids, glucosinolates, etc.). These 
compounds interact with many molecular pathways in promoting health and preventing disease 
states in vitro and in vivo139. Bioactive compounds have demonstrated antioxidant, 
antiinflammatory, and anticancer activities across cell models, animal models, and, most 
importantly, human models18,140,141. Moreover, these compounds seem to have synergistic health 
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promoting effects when consumed in combinations or as whole foods27,142,143. This suggests that 
consuming whole foods and a variety of bioactive compounds are important for the prevention of 
diseases including cancer. Numerous studies investigating anticancer properties in disease 
models have elucidated that bioactive compounds interact with multiple molecular pathways 
influencing cell behavior.  
Sorghum bicolor, known simply as sorghum, is grown primarily for grain production in 
arid parts of the world due to its low water requirements. Sorghums have been reported to be rich 
in phenolics and antioxidants with bioactivity in numerous in vitro and in vivo models. This 
activity is not exclusive to the commonly consumed grain, but also true of the leaves, leaf and 
leaf sheath. In fact, the leaves and leaf sheaths have been used in traditional medicines for the 
treatment of diseases, including cancers. Much less is known about the in vitro and in vivo 
bioactivity the stalk of S. bicolor, nor is there much known with regards to sweet sorghum 
varieties of S. bicolor. Sweet sorghums are varieties of S. bicolor which concentrate sugars in the 
stalk and are grown for making sugars and syrups. Interest has grown in the use of sweet 
sorghum as a biofuel in the biorefinery approach to biofuel production. This generates large 
volumes of biomass, which may serve as reservoirs of human health–promoting bioactive 
compounds. Great Valley Energy LLC has patented technology for separating pith cells from the 
dermal layer of the stalk after separating the leaves and seed head. The main goal of this research 
is to investigate the in vitro and in vivo bioactivity in extracts from the stalk (pith and dermal 
layer) of different varieties of sweet sorghum against colon cancer cells and colon cancer stem 
cells. We also aim to investigate molecular mechanisms responsible for any observed activities 
and to identify phenolic bioactive compounds contained within these extracts. Given the 
predisposition of inflammatory conditions and dietary/lifestyle factors in the promotion of 
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colorectal cancer, we also aim to assess the in vivo antiinflammatory and antioxidant bioactivity 
of dermal extract in a murine high-fat diet induced obesity and inflammation model.
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CHAPTER 2: THE DERMAL LAYER OF SWEET SORGHUM (SORGHUM BICOLOR) 
STALK, A BYPRODUCT OF BIOFUEL PRODUCTION AND SOURCE OF UNIQUE 3-
DEOXYANTHOCYANIDINS, HAS MORE ANTIPROLIFERATIVE AND 
PROAPOPTOTIC ACTIVITY THAN PITH IN P53 VARIANTS OF HCT116 AND 




2.1  Overview. 
There is a growing interest in the utilization of sweet sorghum as a renewable resource for 
biofuels. During the biofuel production process, large quantities of biomass are generated 
creating a rich source of bioactive compounds. However, knowledge of sweet sorghum stalk is 
lacking. We measured phenolic content (Folin-Ciocalteu assay), antioxidant activity (2,2`-azino-
bis (3-ethylbenzothiazoline-6-sulfonic acid) assay) and phytochemical composition (LC-MS) in 
both pith and dermal layer of the stalk. We further tested the antiproliferative (5-bromo-2`- 
deoxyuridine assay) and proapoptotic (terminal deoxynucleotidyl transferase dUTP nick end 
labeling assay) activities of these extracts using HCT116 cells and colon cancer stem cells 
(CCSCs) with and without the tumor suppressor gene p53. For the first time, we show that 
dermal layer extract of sweet sorghum contains more of the 3-deoxyanthocyanidins apigeninidin 
and luteolinidin than pith, and this was associated with more anticancer activity. Furthermore, 
luteolinidin suppressed CCSCs proliferation more than apigeninidin. In addition to being 
renewable biofuel, sweet sorghum may also serve as source of health-promoting compounds. 
Keywords: sweet sorghum, Sorghum bicolor, biorefinery, biofuel, total phenolics, antioxidants, 





Colorectal cancer is the third most common cancer in males and females in the United 
States20, and it has been estimated that 80% of colon cancer cases are caused by diet19. Evidence 
suggests that small molecule bioactive compounds confer the protective and preventive effects 
against chronic diseases, such as cancer, associated with a plant-based diet19. This recent 
understanding has increased the demand for natural sources of plant phytochemicals with 
chemopreventive and chemoprotective properties. In fact, there are multiple clinical trials 
investigating the preventive and therapeutic roles of curcumin, resveratrol, and n-3 
polyunsaturated fatty acids for colon cancer21. 
The progression from normal epithelium to colon cancer is a multistep process whereby a 
normal cell accumulates successive genetic alterations and establishes clones22. The tumor 
suppressor gene p53 is responsible for growth and apoptosis, therefore preventing the 
accumulation of mutated genomes and the progression of cancer144. In colorectal cancers, p53 is 
estimated to be abnormal in 50-75% of cases and marks the transition from preinvasive to 
invasive disease22. It is believed that colon cancer is a disease of aberrant stem cell populations, 
as stem cells have the ability to self-renew for many generations, making them long-lived 
enough to acquire the mutations necessary to manifest the disease145. Cancer stem cells are 
known to be chemotherapy- and radiation-resistant, making them resilient to current standard of 
care therapies133, which often reduce the tumor mass but do not eradicate the disease. Therefore, 
for a treatment to be considered effective against colon cancer, it needs to not only show efficacy 
in colon cancer cells, representing the bulk of the tumor mass, but also against the cancer stem 
cells and cells with loss of p53. There is already in vitro and in vivo evidence supporting the 
efficacy of small molecule bioactive compounds in the selective removal of colon cancer stem 
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cells and cells with abnormal p53. Lin et al. demonstrated that curcumin and a curcumin 
analogue successfully targeted stem cells derived from colon cancer cell lines in vitro137. We 
have previously shown that combination of grape seed extract with resveratrol resulted in p53-
dependent and -independent apoptosis of colon cancer HCT116 cells29. 
Worldwide, sorghum is the fifth most cultivated cereal crop, after rice, wheat, corn, and 
barley1. Sweet sorghums are varieties of Sorghum bicolor which concentrate simple sugars in the 
pith cells of the stalk ranging from 10% to 25%, with glucose and fructose as the main reducing 
sugars12. As a result, they have smaller grain yield and thicker taller stalks when compared to 
grain sorghums12. There is a growing interest worldwide in using sweet sorghum as a 
replacement crop for sugar cane in the production of biofuels. Advantages of sweet sorghum 
over cane sugar include reduced water requirements, shorter growing periods, and reduced 
cultivation cost1. Sweet sorghum can grow in marginal lands and therefore does not have to 
compete with food production1,13.  
Biofuel production of sweet sorghum results in the generation of a large amount of 
biomass2 comprised of stalks, leaves, and leaf sheaths, which is commonly treated as waste or 
utilized as a fodder. In addition, these products, particularly the leaves and leaf sheaths, have 
been used by traditional healers in Africa and India for anemia, epilepsy, stomach ache, and, 
interestingly, cancer.3 Having been reported to be high in phenolic acids and other compounds,44 
it has been shown that sorghums contains high levels of small molecule bioactive compounds in 
the stalk, leaf, leaf sheath, glumes and seed4,5,7,70 with reported bioactive properties62,67,82. 
Apigeninidin and luteolinidin belong to the 3-deoxyanthocyanidin subclass of flavonoids (Figure 
11) and are reported to be expressed in the glume, grain, leaf and leaf sheath4,5,70, in S. bicolor. 
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Furthermore, these compounds have been shown to be potent inhibitors of the HT-29 colon 
cancer cell line8. 
 
Figure 11: Structures of 3-deoxyanthocyanidins reported in this study10. 
This combination of biomass and bioactive compounds makes an attractive combination 
for generating large quantities of bioactive compounds for human health. In a process developed 
by Great Valley Energy LLC, processing of sweet sorghum strips the inner sugary cells of the 
pith from the outer dermal layer resulting in two fractions, the pith and dermal layer. Currently, it 
is unknown if these fractions contain 3-deoxyanthocyanidins, or the contribution of these 
compounds to its bioactivity. The pith is then further processed into biofuel while the dermal 
layer can be processed to make other byproducts in a “biorefinery” approach to making biofuels. 
In this approach, the entire above ground sweet sorghum plant is utilized in creating products, 
which adds value to the process reducing the costs of generating biofuels.15 The aims of this 
paper are to (1) determine the content and composition of the pith and dermal layer from Dale 
and M81E varieties, (2) characterize the antiproliferative and proapoptotic activities of these 
extracts in human colon cancer HCT116 cells and colon cancer stem cells, (3) assess the 
bioactivity of apigeninidin and luteolinidin, (4) determine if p53, a critical tumor suppressor 




2.3 Materials and Methods. 
2.3.1 Chemicals and Reagents. 
 For quantification of total phenolic and antioxidant activity: Sodium bicarbonate, 
monobasic sodium phosphate, dibasic sodium phosphate, and sodium chloride were purchased 
from Fisher Scientific (Pittsburgh, PA); potassium persulfate was purchased from Mallinckrodt 
chemicals (Hazelwood, MO); 2,2`-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) reagent, 
Folin-Ciocalteu reagent, Trolox, and gallic acid were purchased from Sigma (St. Louis, MO).  
For cell culture and experiments, 5-fluorouracil (5-FU) was purchased from Sigma (St. 
Louis, MO). Apigeninidin and luteolinidin were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA) and Indofine Chemical Company (Hillsborough, NJ), respectively. McCoy’s 
media and colon cancer stem cell media were obtained from Sigma (St. Louis, MO) and 
Celprogen (San Pedro, CA), respectively, and fetal bovine serum and streptomycin/penicillin 
mixture were procured from Fisher Scientific (Pittsburgh, PA). 
2.3.2 Sweet Sorghum Materials and Extraction Preparation. 
 Sweet sorghum materials from Dale and M81E varieties used in this study were grown in 
Bakersfield, CA, and generously provided by Great Valley Energy LLC (Bakersfield, CA). Two 
extraction solvents were utilized for the study. Acetone (80%) was identified in the literature and 
empirically as a superior extraction solvent for sweet sorghum dermal and pith layers. Ethanol 
(80%) was used as a GRAS alternative. Fresh sweet sorghum sample (2 g) was extracted with 20 
mL of extraction solvent chilled to -20 °C. This was to prevent excessive heating during the 
homogenization of sample. This mixture was then homogenized for 2 min using an IKA T25 
digital ultra TURRAX at 10 000 rpm. The tubes were then vortexed and the resulting mixture 
was then centrifuged at 4000 rpm for 5 min. The supernatant was filtered using a 0.45 µm PTFE 
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syringe filter (Tisch Scientific; North Bend, OH). The resulting pellet was then resuspended in 
20 mL of extraction solvent by vortexing for 1 min and centrifuged, and supernatant was 
collected and filtered. This was repeated for a third round of extraction, after which the filtrates 
were combined and the final volume was made to 100 mL. The phenolic extracts were then 
stored at -20 °C until analyzed for total phenolics, antioxidant activity and LC-MS. 
Phenolic enriched extracts were prepared by extracting 2 g of sample in 20 mL of 
extraction solvent chilled to -20 °C. This mixture was homogenized for 2 min with an IKA T25 
Digital Ultra TURRAX set to 10 000 rpm. The homogenate was then placed on a reciprocal 
shaker overnight in the dark at 4 °C to allow for diffusion of phenolics to create an enriched 
extract. The mixture was then centrifuged and the supernatant was filtered with 0.45 µm PTFE 
filters (Tisch Scientific). Extracts prepared with 80% acetone were dried in a Buchi rotavapor 
(Flawil, Switzerland) to remove the acetone. The aqueous portion was then lyophilized, which 
yielded a brown powder. This was re-dissolved in 80% ethanol, aliquoted and stored at -80 °C. 
Extracts prepared with 80% ethanol were concentrated under nitrogen flow in a 35 °C water bath 
for 10 h. Extracts were then aliquoted and stored at -80 °C.  
2.3.3  Quantification of Dry Matter, Total Phenolics and Antioxidant Activity. 
 Dry matter quantification was determined by freeze drying 2 g samples in triplicate and 
measuring changes in weight due to water loss. Results were expressed as percent dry matter. 
For quantification of total phenolics, the Folin-Ciocalteu assay was used as described in 
Singleton’s work52 with minor modifications. In triplicate, 35 µL of extract, standard, or solvent 
was added to individual wells of a 96-well plate followed by the addition of 150 µL of 1 N Folin-
Ciocalteu reagent. The contents were mixed and allowed to react for 5 min under dark 
conditions. After 5 min, 115 µL of 7.5% sodium bicarbonate was added, and the contents were 
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mixed and incubated in the dark at 45 °C for 30 min. The plate was then cooled for 1 h in the 
dark at room temperature. Finally, the absorbance was measured at 765 nm with a Biotek 
Synergy 2 plate reader (Winooski, VT). Gallic acid was used as a standard, and equivalency was 
calculated from a linear regression of standard concentrations. Data are reported as mean 
milligram gallic acid equivalents per gram of sweet sorghum sample (mg GAE/g) ± standard 
error.  
Antioxidant activity was measured by the ABTS assay as previously described6,146 with 
minor modifications. In brief, 3 mM ABTS radical and 8 mM potassium persulfate were mixed 
and reacted for at least 12 h at room temperature in the dark. Then this solution was mixed 1:30 
with pH 7.4 phosphate buffer to create a working ABTS solution. In triplicate, 290 µL of the 
working solution was added to 10 µL of sample, standard, or solvent in a 96-well plate. This was 
allowed to react for 30 min at room temperature under dark conditions, after which the 
absorbance was measured at 734 nm using the aforementioned plate reader. The antioxidant 
activity is expressed as mean (n = 3) milligram Trolox equivalents per gram of sweet sorghum 
sample (mg TE/g) ± standard error.  
2.3.4 LC-MS Analysis. 
For LC-MS analysis, ethanolic extracts prepared from the pith and dermal of Dale variety 
were concentrated 10-fold before one µL of sample was injected into a Waters Acquity UPLC 
system fitted with a Waters Acquity UPLCT3 column (1.8 µM, 1.0 X 100 mm). The sample was 
injected in 100% solvent A (water, 0.1% formic acid) and this was held for 1 min. This was 
followed by a 12 min linear gradient to 95% solvent B (acetonitrile, 0.1% formic acid). The flow 
rate was held constant at 200 µL/min for the complete run. The column temperature was 50 °C 
and samples were held at 5 °C. 
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Eluent from the UPLC was infused into a Waters Xevo G2 Q-Tof MS instrument fitted 
with an electrospray source. Data were collected in the positive ion mode, scanning from 50 to 
1,200 at a rate of 0.2 s per scan, alternating between MS and MSE mode. The collision energy 
was set to 6 V for MS and 15-30 V for MSE mode. The capillary voltage was set to 2 200 V, the 
source temperature was 150 °C, the desolvation temperature was 350 °C, and the desolvation gas 
flow rate was 800 L/h of nitrogen. Waters raw data files were converted to .cdf format using 
Databridge software (Waters), and feature detection was performed using XCMS. Raw peaks 
were normalized to total ion signal in R. The UPLC-MS system was quality checked by making 
five injections of a standard solution containing 2 µg/mL each of caffeine, reserpine, 
sulfadimethoxine, and terfenadine in 50% methanol. The performance is evaluated using the 
final three injections, and acceptable performance is indicates by a retention time +/- 0.05 
minutes, peak area RSD of < 25%, and mass accuracy of < 3ppm error for all four compounds. 
Calibration was performed prior to analysis via sodium formate, with mass accuracy within 1 
ppm. Compounds were identified by comparing MS spectra obtained from LC-MS analysis to 
NIST, METLIN and MassBank databases using 10 ppm as the upper limit for accuracy. In cases 
where spectra were not obtainable, accurate mass was used to identify compounds. 
2.3.5 Cell Lines and Culturing Procedures. 
HCT116 and HCT116 p53-/- cells were generously provided by Dr. Bert Vogelstein 
(School of Medicine, Johns Hopkins University, Baltimore, MD). Colon cancer stem cells 
(CCSCs) positive for CD34, CD 44 and CD133 were purchased from Celprogen. All cells were 
maintained at a temperature of 37 °C and 5% CO2. HCT116 cells were maintained in McCoy’s 
media with 5% FBS. For experiments, HCT116 cells were treated in 10% charcoal stripped 
serum McCoy’s media. CCSCs were maintained in colon cancer stem cell media (Celprogen). 
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For experiments, CCSCs were treated in serum free colon cancer stem cell media (Celprogen). 
Concentrated extracts were dosed in media normalized to total phenolics content as assessed by 
Folin-Ciocalteu assay. We used 80% ethanol and 5-FU as negative and positive controls, 
respectively.  
2.3.6 Lentiviral shRNA Mediated Knockdown of p53 in CCSCs. 
CCSCs were transfected with lentiviral particles encoding shRNA targeting p53 (Santa 
Cruz Biotechnology Inc. Santa Cruz, CA) according to the supplier’s protocol. Briefly, CCSCs 
were infected at a multiplicity of infection of 10 in CCSCs growth medium containing 5 μg/mL 
of polybrene at 37 °C and 5% CO2. After 24 hours, media was replaced and the cells were 
cultured for 2 d. Transfected cells were then selected in the presence of puromycin (7.5 μg/mL) 
for an additional 5 d, and p53 suppression confirmed by Western blotting (Figure 12). 
 
Figure 12. p53 expression in CCSCs with and without p53 shRNA. 
 
2.3.7 Proliferation and Apoptosis. 
 Cell proliferation was assessed via 5-bromo-2`- deoxyuridine (BrdU) assay (Cell 
Signaling Technologies; Beverly, MA) and cell counting using an automated cell counter 
(Nexcelom Bioscience, Lawrence, MA). Briefly, HCT116 cells and CCSCs were grown in 96-
well plates at 2 X 104 cells per well. After 24 h, the media was aspirated, and the cells were 
treated with controls and sweet sorghum extracts. The treatments were added in triplicate at the 
volume of 150 µl per well and then allowed to incubate for 20 h at 37 °C. At this point, BrdU 
was added at a concentration of 10 µM per well and incubated at 37 °C for an additional 4 h to 
allow incorporation of BrdU into cellular DNA (24 h total). The media was removed and the 
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BrdU assay was performed according to manufacturer’s protocol. For cell counting, cells were 
seeded at 1 X 105 cells per well in 12-well plates. After 24 h, control compounds and sweet 
sorghum extracts were added at a volume of 1 mL per well. After 24 h, cells were removed from 
plates and cells counted according to manufacturer’s protocol.  
Apoptosis was analyzed by measuring active caspase activity with a Caspase-Glo 3/7 
assay kit (Promega Corp.; Madison, WI) and confirmed with the terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) method. For measuring caspase activity, cells were 
seeded and treated with control compounds and test extracts the same as in the cell counting 
experiments. After 24 h of incubation, 100 µL of HCT116 cells and CCSCs were transferred into 
a white 96-well plate and the Caspase-Glo 3/7 assay was performed according to the company’s 
protocol. The data was normalized to cell count and expressed as percent of the solvent control. 
For TUNEL, cells were seeded into 4 well chambered glass slides at a density of 1 X 105 cells 
per chamber. After treatments, the slides were prepared and analyzed for TUNEL staining 
according to manufacturer’s protocols (Roche Diagnostics; Indianapolis, IN). For analysis, 10 
images from each well containing were taken containing at least 50 cells per image. Cells were 
counted and data expressed as the percentage of TUNEL positive cells to total cells (percent 
apoptosis). 
2.3.8  Colony Formation Assay. 
 The colony formation assay was performed as described147 with slight modifications. 
Colon cancer stem cells were seeded at 1.5 X 105 cells per well in a six-well tissue culture plate 
(TPP; St Louis, MO). After adhesion (24 h), the cells were treated with controls and test 
compounds for 24 h. The cells were then replated at a density of 100 cells per well in another 
six-well tissue culture plate and colony formation was measured as described148.  
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2.3.9 Statistical Analysis. 
 Data are presented as means ± standard error. Statistical significance was determined by 
one way ANOVA, followed by the post-hoc Fisher least significant difference test for multiple 
means comparisons using IBM’s SPSS v21. Means not sharing the same letter were statistically 
significant (P < 0.05).  
2.4 Results and Discussion. 
Sweet sorghum processing generates significant amounts of biomass containing bioactive 
phytochemicals and represents a promising source of human health-promoting bioactive 
compounds. In this study, the dermal and pith of two varieties of sweet sorghum were grown, 
processed, and analyzed for total phenolics and antioxidant activity. The effects of sweet 
sorghum pith and dermal layer extracts on colon cancer stem cell proliferation, apoptosis, and 
stemness were also studied. For cell based experiments, cells were dosed with sweet sorghum 
phenolic rich extracts based on microgram gallic acid equivalents per milliliter media (µg 
GAE/mL), which was determined by the Folin-Ciocalteu assay.  
2.4.1 Dry Matter, Total Phenolics, Antioxidant Activity, and LC-MS Analysis. 
 For dry matter content, we observed similar levels of dry matter of pith and dermal 
samples across both Dale and M81E varieties. The dry matter content is summarized in Table 7. 
The dry matter of Pith from Dale and M81E was 22%. The dry matter content of dermal layer 
was 39% and 42% for Dale and M81E, respectively (Table 7). These findings are in agreement 
with previously published data reporting dry matter content for pith of sweet sorghum stalks to 
contain 30% dry matter44, reflecting the high moisture content necessary to store and concentrate 
sugars. To the best of our knowledge, this is the first study reporting the difference between the 
moisture content in pith cells and dermal cells of sweet sorghum.  
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 dermal pith  dermal pith 
TPb 172 ± 6a 127 ± 5b  225 ± 11c 88 ± 3d 
ABTSc 570 ± 54a 248 ± 12b  365 ± 12c 128 ± 12d 
dry matter 39.0 ± 0.7a 21.6 ± 0.2b  42.2 ± 0.8c 21.5 ± 0.3b 
Values are presented as means (n = 3) ± standard error. Different online Roman letters within a row 
indicate significant differences (P < 0.05) among the entries. bTP, total phenolics analyzed by Folin-
Ciocalteu method, expressed as milligram of gallic acid equivalents per 100 g fresh mass. 
cantioxidant activity as analyzed by ABTS assay, expressed as milligram Trolox Equivalents per 100g. 
 
We next sought to characterize the total phenolics and antioxidant activities of sweet 
sorghum stalk components. Acetone (80%) extracts were used to determine total phenolics and 
antioxidant activities of sorghum samples by Folin-Ciocalteu and ABTS, respectively (Table 7). 
The total phenolics content of the dermal layer was higher than that of pith in both varieties by 
35% and 155% in Dale and M81E, respectively. A similar relationship was also observed in the 
antioxidant activity. Amongst the two varieties, Dale dermal extracts yielded more Trolox 
equivalents, yet fewer gallic acid equivalents as assessed by ABTS and Folin-Ciocalteu assays, 
respectively (P < 0.05). When pith and dermal are combined there is no difference between the 
gallic acid equivalents of Dale and M81E, but there is significantly more Trolox equivalents. 
This could be a resultant of a difference in the compositions of phenolic, antioxidant, and other 
reducing substances contained in the two varieties. Reducing sugars such as sucrose, fructose 
and glucose are concentrated in the pith of sweet sorghum and contribute to total phenolics 
readings. Reducing sugars are known to be approximately twice as concentrated in the pith as in 
other components of the stalk44 and differences in reducing sugars could explain this 
discrepancy.  
We next sought to analyze bioactive compounds from the pith and dermal components of 
sweet sorghum stalk by LC-MS analysis. We were able to identify phenolic acids, flavonoids and 
45 
 
stilbenoids from the phenolic extracts of sweet sorghum pith and dermal layer, which are 
summarized in Table 8. These compounds have been identified previously in sorghum and have 
also been reported to have potent in vitro and in vivo anticancer activities. For example, we were 
able to identify luteolinidin and apigenidin, which have been previously reported in leaf sheaths 
and leaves of sorghum4,70. These compounds have been reported to have anticancer activities 
toward a number of cancer cell lines including liver, leukemia and colon8,10,82.   
Table 8. Compounds identified in sweet sorghum by LC-MS analysis. 











vanillic acid C8H8O4 2.79 169.050 169.0495 2 100.9 ± 3.8 68.2 ± 7.4 f 5 
p-coumaric 
acid 
C9H8O3 0.85 165.055 165.0546 2 534.9 ± 14.6 492.0 ± 23.8 5 
ferulic acid C10H10O4 3.12 195.067 195.0652 9 27.6 ± 1.8 14.3 ± 1.5 f 5 
caffeic acid C9H8O4 3.16 181.050 181.0495 2 152.4 ± 1.3 26.5 ± 4.5 f 5 
apigeninidin C15H11O4+ 4.29 255.066 255.0660c 0 96.5 ± 20.2 7.9 ± 0.7 f 4,5,70 





4.76 493.134 493.1314c 3 168.6 ± 5.7 12.7 ± 1.4f 4 
apigenin C15H10O5 4.04 271.061 271.0607 3 71.2 ± 53.8 8.6 ± 1.2 5 
luteolin C15H10O6 5.48 287.056 287.0556 3 47.3 ± 54.2 4.6 ± 3.0 5,72 
trans-
resveratrol 
C14H12O3 8.48 229.087 229.0859 4 28.8 ± 3.3 37.6 ± 2.9 5 
luteoferol C15H14O6 4.26 291.087 291.0863 2 16.3 ± 0.8 6.4 ± 0.3*  
aFormulas are based on [M]. bExact masses are based on [M+H]+ unless otherwise indicated. cMass based on 
[M]. dNormalized peak intensities based on peak areas normalized to total ion signal in R. eReferences which 
have previously identified the compound listed. fSignificant differences (P < 0.05) observed among dermal and 
pith. 
 
Previous studies have identified primarily 2 major classes of bioactive phenolic 
compounds, phenolic acids and flavonoids, in sorghums and sweet sorghums. These 
investigations primarily focused on the grains or seed heads from grain sorghum for its relevance 
as a staple in human diets. Other investigations have focused on the leaf, leaf sheath, infected 
sorghum seedlings, and glume4,7,70,72, and these parts of the plants are pertinent to traditional 
medicine. These studies have identified multiple phenolic compounds with potent in vitro and in 
vivo activities. These include phenolic acids, anthocyanidins, and flavones. Few studies have 
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investigated sweet sorghum with respect to its bioactive content, especially the stalk components, 
pith and dermal. On the basis of these observations, we hypothesized that extracts from the sweet 
sorghum stalk components pith and dermal layer, containing multiple bioactives would suppress 
proliferation and induce apoptosis in colon cancer cells.  
2.4.2 Anticancer Activities of Sweet Sorghum Pith and Dermal Extracts. 
 Early in the pathogenesis of colorectal cancer, hyper-proliferation of colonocytes 
resulting from a deregulation of cellular proliferation and a suppression of apoptosis results in 
the formation of aberrant crypt foci and, subsequently, adenomas. Colon stem cells, residing in 
the base of the crypt, are responsible for renewing the colonic epithelium during one’s 
lifetime149. Furthermore, they are long-lived, self-renewing cells and have a high capacity for 
proliferation, a combination that makes them a likely candidate to acquire the mutations 
necessary to give rise to colon cancers122. Today’s therapies are ineffective at targeting cancer 
stem cells, only targeting the bulk of the rapidly dividing tumor cells145. Therefore, effective 
treatment strategies for colon cancer should suppress proliferation and induce apoptosis in the 
rapidly dividing tumor mass as well as the cancer stem cells. This would rid the tumor mass of 
the tumor promoting stem cells as well as remove the bulk of the tumor. We assessed the pith’s 
and dermal layer’s bioactivity by measuring (1) antiproliferative effects in colon cancer HCT116 
cells and CCSCs as evaluated by cell count and BrdU assay, (2) proapoptotic effects in HCT116 
cells and CCSCs cells as evaluated by activated caspase 3/7 activity and subsequently confirmed 
by TUNEL assay, and (3) self-renewal in CCSCs as analyzed by colony forming assay.  
2.4.3 Differential Activities of Pith and Dermal Extracts. 
 To investigate the differences in the anticancer effects between pith and dermal extracts, 
colon cancer HCT116 cells were treated with phenolic rich extracts prepared from Dale pith 80% 
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acetone extract (PAE) and Dale dermal 80% acetone extract (DAE) for 24 h as shown in Figure 
13. Extract from DAE suppressed cell proliferation more than PAE, as shown by cell count and 
BrdU assays. This may be due to higher levels of reducing sugars in the pith. At 25 µg GAE/mL, 
DAE suppressed cell count 43% compared to only an 11% reduction for PAE. IC50 values were 
calculated for PAE and DAE. The IC50 for PAE was calculated to be above 50 µg GAE/mL, 
while DAE was calculated to be 36 µg GAE/mL. DAE was also able to induce apoptosis at 
lower concentrations than pith as measured by caspase activity. At concentrations of 12.5, 25, 
and 50 µg GAE/mL, DAE was able to increase active caspase levels to 155%, 159%, and 184% 
to that of a solvent control, respectively. Only 50 µg GAE/mL of PAE was able to increase 
active caspases 3 and 7 in HCT116 cancer cells (169%, P < 0.05). These data implicated DAE as 
a more effective antiproliferative and proapoptotic extract than PAE, and therefore further 
experiments focused solely on extracts from the dermal layer of the Dale variety. These 
differences in bioactivities between the pith and dermal layer of the Dale variety stalk may be 
explained by the differences in their composition and content of bioactive compounds. These 
results are analogous to differences observed in the bioactivities of different parts of edible fruits. 
For example, only the ethanolic extracts from the peel of mango, but not the flesh, induced 
apoptosis in cervical cancer HeLa cells150. Interestingly, our LC-MS analysis of pith and dermal 
extracts showed marked and significant differences between extracts from dermal and pith 
(Table 8). For example, the ethanolic pith extract contained only 8% of the apigeninidin and 5% 
of the luteolinidin as compared to the levels of these compounds in the ethanolic dermal extract 





Figure 13. Antiproliferative proapoptotic activities of Dale dermal and pith phenolics measured 
by (A) cell count and (B) BrdU assay, and (C) Caspase 3/7 Glo assay. HCT116 cells were treated 
for 24 h with acetone extracts (DAE and PAE) at 10, 12.5, 25, and 50 µg GAE/mL before 
estimation of proliferation and apoptosis. Values are presented as percent of the solvent control. 
For cell count and Caspase 3/7 Glo, means (n = 2) ± standard deviation are presented. For BrdU, 
means (n = 3) ± standard error are presented. Different letters indicate significant differences (P < 
0.05) among treatments. Solvent = solvent control; and 5FU = 5-fluorouracil (18 µg/mL). 
 
2.4.4  Solvent-dependent Activities of Dermal Extracts. 
 Previous quantitative and in vitro experiments demonstrated that aqueous acetone makes 
a good extraction solvent for dermal phenolic compounds with antioxidant and anticancer 
activity. However, acetone is not an environmentally safe solvent for extraction of bioactive 
compounds, especially for extracts intended for human consumption. Turkmen and colleagues151 
tested the ability of different organic solvents with varying percentages of water to extract 
phenolics from mate and black tea. They found that while 100% ethanol was ineffective at 
extracting tea polyphenols, addition of 20% water increased polyphenol extraction by 
approximately 27 times when compared to 100% ethanol. Furthermore, 80% ethanol yielded 
approximately 60% of the phenolics as that of 80% acetone. On this basis, we hypothesized that 
ethanol, a GRAS organic solvent, with water could be used to extract phenolics from sweet 
sorghum dermal layer with similar effectiveness as aqueous acetone. Similar to Turkmen’s 
findings, 80% ethanol yielded approximately 84% compared to 80% acetone (data not shown). 
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We next tested the bioactivity of the phenolic rich dermal extract prepared from 80% ethanol 
(DEE) in HCT116 and compared it to DAE. As demonstrated by Figure 14, DEE had a superior 
IC50 value of 22 compared to the IC50 of 36 µg GAE/mL for DAE. Given the GRAS status of 
ethanol and the greater in vitro bioactivity against HCT116 cells, further experiments utilized 
DEE. We further tested DEE for proapoptotic activities by the Caspase 3/7 Glo assay and 
TUNEL assay. When compared to solvent control, DEE at all concentrations significantly 
increased apoptosis. Furthermore, this increase in apoptosis was more than the positive control 5-
FU, which was used in this study as a comparison of sweet sorghum extracts to a standard 
chemotherapeutic agent. Our findings highlight the important aspect of solvent selection when 
extracting and analyzing in vitro bioactivities of plant-based extracts.  
 
Figure 14. Dose-response curves for HCT116 cells. Cells were treated for 24 h with pith and 
dermal phenolic rich extracts prepared by extraction with either acetone (AE) or ethanol (EE). The 
response is based on cell proliferation as estimated by cell counting. Simple linear regression was 
used to estimate IC50 values. Values are presented as percentages of the solvent control (% Control) 
(y axis) at a specific dose of the respective phenolic-rich extract in micrograms of GAE per 
milliliter (µg GAE/mL) (x axis).  
 
2.4.5 DEE Effectively Eliminates Colon Cancer Stem Cells.  
 There is growing evidence that cancers arise from a small population of adult cancer stem 
cells. They are also resistant to many standard of care therapies (e.g. chemotherapy and 
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radiotherapy), and the inability to rid the body of these persistent cells is thought to be a primary 
cause of colon cancer recurrence133. There is a need for standardized bioactive compounds and 
extracts that can effectively eliminate these cells, as current anticancer drugs often fail133. We 
tested DEE against colon cancer stem cells and compared it to 5-FU, a common 
chemotherapeutic for the treatment of colon cancer. We treated colon cancer stem cells with 
DEE at 8.75, 17.5 and 35 µg GAE/mL, and 5-FU (18 µg/mL, 100 µM) for 24 h and measured 
proliferation, and apoptosis (Figure 15 and 16). DEE potently suppressed proliferation to73% of 
control, as measured by BrdU, and increased the percentage of TUNEL positive cells from 7% to 
95% of total cells (P < 0.05). Imaging of TUNEL stained cells (Figure 16C) shows increases in 
DNA fragmentation (increased fluorescence) and changes in cell morphology consistent with 
apoptosis. We further tested the antiproliferative activity of apigeninidin and luteolinidin against 
CCSCs with BrdU assay and IC50 were calculated as demonstrated in Figure 15C. Luteolinidin 
suppressed CCSC proliferation more than apigeninidin, as demonstrated by a lower IC50 value of 
76 µg/ml as compared to > 160 µg/mL. 
 
Figure 15. Antiproliferative activities of Dale dermal phenolics measured by (A) cell count, B) 
BrdU assay, and (C) Antiproliferative activities of apigeninidin (Api) and luteolinidin (Lut) 
measured by BrdU. Colon cancer stem cells (CCSCs) were treated for 24 h with dermal phenolic 
rich ethanol extracts of Dale variety (DEE) at 8.75, 17.5, and 35 µg GAE/mL before estimation of 
proliferation. Values are presented as percent of the solvent control (% Control). For cell count, 
means (n = 2) ± standard deviation are presented. For BrdU, means (n = 3) ± standard error are 
presented. Different letters indicate significant differences (P < 0.05). Solvent = solvent control; 






Figure 16. Proapoptotic activities of Dale dermal phenolics measured by (A) Caspase 3/7 Glo 
assay, and (B) TUNEL assay. Colon cancer stem cells (CCSCs) and HCT116 cells were treated 
for 24 h with dermal phenolic rich ethanol extracts of Dale variety (DEE) at 8.75, 17.5, and 35 µg 
GAE/mL before being tested. Values are presented as mean (n = 2) percentages of the solvent 
control ± standard deviation. (C) Representative images of CCSCs from TUNEL assay. Different 
letters indicate significant differences (P < 0.05) among treatments. Solvent = solvent control; and 
5FU = 5-fluorouracil (18 µg/mL). 
 
To further assess DEE’s ability to target CCSC properties other than proliferation and 
apoptosis, the self-renewal capability of CCSCs’ self-renewal was measured by colony forming 
assay (Figure 17). We treated CCSCs with DEE and found a dose-dependent suppression in 
DEE 35 
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colony formation. Figure 17B shows representative images collected from the colony forming 
assay and demonstrates the decreased colony number and size associated with treatment in 
comparison to the control. At the highest concentration, DEE completely suppressed CCSC 
colony formation, and this activity was greater than that of 5-FU treatment. This demonstrates 
that, in addition to the antiproliferative and proapoptotic activities, DEE alters the stemlike 
properties by inhibiting colon cancer stem cell self-renewal than 5-FU.  
  
Figure 17. Effects of Dale dermal phenolics on colony formation. (A) Colon cancer stem cells 
(CCSCs) were treated for 24 h with dermal phenolic rich ethanol extracts of Dale variety (DEE) 
at 8.75, 17.5, and 35 µg GAE/mL before estimation of colony formation by colony forming assay. 
(B) Representative images taken from the colony forming assay. Values are presented as the mean 
(n = 3) number of colonies formed containing at least 50 cells ± standard error. Different letters 
indicate significant differences (P < 0.05) among treatments. Solvent = solvent control; and 5FU 
= 5-fluorouracil (18 µg/mL). 
 
There has been little research done on the in vitro anticancer activities of sorghum stalk, 
especially sweet sorghum, on cancer cells and advanced cancer stem cells. Research from Yang 
et al.8 demonstrated that grain extracts from pigmented grain sorghums contained high levels of 
3-deoxyanthocyanins and had strong antiproliferative activities in vitro against colon cancer HT-
29 cells. Furthermore, they tested the antiproliferative effects of individual 3-
deoxyanthocyanidins. They reported IC50 values ranging from 180 to 557 µg/mL for crude 
extracts and approximately 13 to 20 µg/mL values for 3-deoxyanthocyanidins. In agreement with 
Yang’s findings, we too have demonstrated that phenolic rich extract from the dermal layer of 
53 
 
sweet sorghum stalks contains 3-deoxyanthocyanidins and has potent antiproliferative and 
proapoptotic activities. The fact that dermal phenolic rich extract has activities in colon cancer 
cells and colon cancer stem cells highlights a need for further research of sweet sorghum’s 
anticancer activity in vivo for its potential as a chemotherapeutic agent against colon cancer.  
2.4.6  Effects of p53 on the Anticancer Activity of DEE. 
 The p53 tumor suppressor gene is an integral regulator of cell cycle control, DNA repair 
and apoptosis21. It is estimated that half of all tumors carry some form of mutated p5325. 
Effective preventive and therapeutic colon cancer strategies should successfully target p53-
dependent and -independent pathways. To test the p53-dependency of DEE’s anticancer activity, 
we treated HCT116 p53-/- cells carrying p53 deletions in both alleles of the p53 gene with DEE 
for 24 h and measured changes in proliferation and caspase activity (Figure 18). We observed no 
significant changes between HCT116 p53-/- cells treated with DEE and solvent controls in 
cellular proliferation as measured by the BrdU assay, indicating that DEE’s ability to suppress 
cellular proliferation is p53-dependent. However, we did observe a significant increase in active 
caspase activity at the highest dose of DEE. This indicates that DEE may act through p53-
independent pathways of apoptosis only at concentrations at and above 35 µg GAE/mL and this 
may also be true of DEE’s antiproliferative effects. 
We further tested p53-dependency in CCSCs by knocking down p53 expression with 
lentiviral infection containing p53 shRNA (CCSCs p53 shRNA). The shRNA is constitutively 
expressed due to the presence of a strong promoter binding to p53 mRNA preventing its 
translation. In this model of p53 knockdown, DEE suppressed proliferation up to 33% of control 





Figure 18. Antiproliferative and proapoptotic activities of Dale dermal phenolics in p53 variants 
of CCSCs and HCT116 cells measured in a p53-independent manner as measured by (A) BrdU 
assay, (B) Caspase 3/7 Glo assay, and (C) TUNEL assay. The antiproliferative effects of 
apigeninidin and luteolinidin were also measured by BrdU assay. Colon cancer stem cells (CCSCs) 
with p53 shRNA and HCT116 p53-/- cells were treated for 24 h with dermal phenolic rich ethanol 
extracts of Dale variety (DEE) at 8.75, 17.5, and 35 µg GAE/mL before being tested. For BrdU 
assay, values are presented as mean (n = 3) percentages of the solvent control ± standard error. For 
Caspase 3/7 Glo and TUNEL assays, values are presented as mean percentages (n = 2) of the 
solvent control ± standard deviation. Different letters indicate significant differences (P < 0.05) 
among treatments. Solvent = solvent control; and 5-FU = 5-fluorouracil (18 µg/mL). 
 
BrdU and TUNEL assays (Figure 18). We further tested the antiproliferative effects of 
apigeninidin and luteolinidin in CCSCs p53 shRNA cells with BrdU (Figure 18). We show 
thatoth of the 3-deoxyanthocyanidins suppress proliferation in p53 knockdown cells with IC50 
values of > 160 and 103 µg/mL for apigeninidin and luteolinidin, respectively. In agreement with 
previous results, the antiproliferative effects of luteolinidin surpassed that of apigeninidin. Our 
findings may be due to the slight variation in structure, as luteolinidin contains one extra 
hydroxyl group on the 3` carbon of the B-ring of the flavonoid structure, and has been shown to 
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have a 3-fold increase in antioxidant activity when compared to apigeninidin71. Our findings 
agree with Marko et al.,109 who reported increased activity of anthocyanidins with a higher 
degree of B-ring hydroxylation. 
In this study, we demonstrated differential activity observed between CCSCs and the 
early stage HCT116 cell lines. This differential activity is thought to be a result of the selective 
toxicity of complex bioactive extracts against cancer cells as compared to normal epithelial cells. 
Earlier staged and more differentiated cancer cell lines more resemble the normal differentiated 
epithelial cells than do more advanced cancer cell lines. This was demonstrated in work by 
Seeram et al.152 with total cranberry extract in four colon cancer cell types (SW480, SW620, 
HCT116 and HT29). SW480 and SW620 represent two cell lines from the same patient. The 
former representing the earlier staged primary tumor and the latter derived from a metastasis. 
Total cranberry extract showed 35% more antiproliferative activity against the advanced 
metastatic SW620 cell line when compared to SW480 cells. HCT116 and HT29 cells are both 
colon cancer cell lines representing early and late stage disease, respectively. Total cranberry 
extract showed greater proliferation inhibition activity in the advanced HT29 cell line when 
compared to HCT116 cells. These reports corroborate our findings that sweet sorghum extract 
was more efficacious against CCSCs as compared to HCT116 cells. While our results point to 
p53-independent activity, more work is needed to determine the mechanisms of DEE.  
In the present study, we have shown for the first time that the dermal layer of sweet 
sorghum is rich in total phenolics and antioxidants including 3-deoxyanthocyanidins with potent 
in vitro anticancer activity against colon cancer HCT116 cells and CCSCs. This activity was 
greater than that of pith and we believe this to be due to the different compositions of phenolics 
as illustrated in Table 8. Furthermore, we demonstrated that the ethanolic extract was more 
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potent in suppressing the proliferation of colon cancer cells highlighting the importance of 
solvent selection in developing natural based phenolic rich extracts. In addition to being a source 
of renewable biofuel, sweet sorghum may also serve as source of health-promoting compounds 
for the prevention and treatment of inflammatory diseases such as colon cancer. For this to be a 
reality, further research is needed to determine potential toxicities and the bioactivities of sweet 





CHAPTER 3: EXTRACTS FROM SWEET SORGHUM (SORGHUM BICOLOR), A 
FEEDSTOCK FOR BIOREFINING, SUPPRESSED PROLIFERATION AND 
ELEVATED APOPTOSIS IN HUMAN COLON CANCER STEM CELLS VIA 






 In colorectal cancer, p53 is commonly inactivated, associated with chemotherapy-
resistance, and marks the transition from non-invasive to invasive disease. Cancers, including 
colorectal cancer, are thought to be a disease of aberrant stem cell populations, as stem cells are 
able to self-renew, making them long-lived enough to acquire mutations necessary to manifest 
the disease. We have shown that extracts from sweet sorghum stalk components kill colon cancer 
stem cells (CCSCs) in a p53-independent fashion. However, the underlying mechanisms are 
unknown. In the present study, CCSCs were transfected with short hairpin-RNA against p53 
(CCSCs p53 shRNA) and treated with sweet sorghum phenolics extracted from different plant 
components (dermal layer, leaf, seed head and whole plant). While all components demonstrated 
antiproliferative and proapoptotic effects in CCSCs, phenolics extracted from the dermal layer 
and seed head effectively killed CCSCs by increasing effector caspase activity, PARP cleavage, 
and DNA fragmentation in a p53-dependent and partial p53-dependent fashion, respectively. 
Further investigations revealed the antiproliferative and proapoptotic effects were associated 
with decreases in β-catenin protein levels, and β-catenin targets Cyclin D1, cMyc, and Survivin. 
These results suggest that the antiproliferative and proapoptotic effects of sweet sorghum 
extracts in CCSCs work via decreasing β-catenin prosurvival signaling in a p53-dependent 
(dermal layer) and p53-independent (seed head) fashion.  




3.2 Introduction.  
Colorectal cancer is the third most common cancer in males and the second most 
common in females153, and up to 80% of colon cancer cases are thought to be caused by diet19. 
Recent evidence implicates that bioactive compounds (e.g. phenolic acids, flavonoids, 
stilbenoids, carotenoids) are responsible for imparting protective and preventive properties 
against chronic diseases19. This understanding has increased the demand for natural products 
meant to protect and prevent against diseases such as colorectal cancer.  
The process by which a normal epithelium progresses to colon cancer is multi-step, 
whereby normal cells accumulate successive genetic alterations and establish clones22. In 
colorectal cancers, aberrant WNT/β-catenin signaling occurs in almost all cases and drives 
carcinogenesis23,24. However, further genetic events must occur to fully develop disease 
malignancy24. The traditional pathway to colorectal cancer accounts for 70% to 85% of all 
cancers22. This pathway starts with loss or mutation of APC resulting in β-catenin accumulation, 
followed by mutation in K-ras, loss of 18q, and finally loss of p53 via loss of 17p22. p53 is 
responsible for cell growth and apoptosis, therefore it prevents the build-up of mutated genomes 
and the advancement of cancer. It is estimated that p53 is abnormal in 50% to 75% of colorectal 
cancer cases, and this marks the transition from noninvasive to invasive disease22. Disruption of 
p53 is known to alter tumor responses to 5-Fluorouracil based therapies making it more difficult 
to effectively eliminate colorectal tumors by conventional chemotherapies26. Situations such as 
these create a need for new therapies which can target these drug resistant tumors. 
β-catenin accumulation is understood to be an important driver in the carcinogenesis of 
colorectal cancers. It is present in both familial and sporadic forms of the disease. Excess β-
catenin accumulation promotes transcriptionally active p53154. In addition, active p53 results in 
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the degradation of β-catenin155. β-catenin is further regulated by GSK-3β, which phosphorylates 
β-catenin at the N-terminus of the protein156. Binding of APC and Axin to GSK-3β and β-catenin 
facilitates this event and results in the ubiquitination and degradation of β-catenin156. In the 
absence of such regulation, β-catenin accumulates in the cytosol and translocates to the nucleus 
where it interacts with members of the Tcf/Lef family of transcription factors resulting in 
transactivation of prosurvival target proteins, such as cMyc, Cyclin D1, and Survivin123. GSK-3β 
itself is regulated by several phosphorylation events, impacting its ability to control β-catenin 
levels. The phosphorylation of serine residues (e.g. S9) results in decreased GSK-3β activity, 
while phosphorylation of tyrosine residues (e.g. Y219) results in its activation157. 
Currently, it is believed that aberrant stem cell populations are the root cause of 
colorectal cancers, as stem cells are able to self-renew, making them long-lived enough to 
acquire mutations necessary to manifest the disease145. Interestingly, it has been shown that 
Wnt/β-catenin signaling defines colon cancer stem cells in the tumor situation125. Furthermore, 
they are known to be chemo- and radiation-resistant making it difficult to treat with current 
standard of care practices133, which often fail to fully eradicate the disease. It is imperative, 
therefore, that a cancer treatment show efficacy in the stem cell population and populations with 
aberrant β-catenin signaling and loss of p53. There is evidence for the efficacy of bioactive 
compounds in the selective removal of cancer stem cells and cancer cells with abnormal p53. 
Resveratrol was shown to inhibit prostate cancer stem-like cells by targeting fatty acid 
synthesis158. Curcumin and a curcumin analogue successfully targeted stem cells derived from 
colon cancer cell lines137. We have shown the combination of grape seed extract with resveratrol 
resulted in p53-dependent and p53-independent apoptosis in colon cancer HCT116 cells29. This 
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evidence warrants further investigation into the development of novel bioactive compound 
treatments for colorectal cancer.  
Sorghum is an important food source worldwide, placing fifth in cereal crop cultivation1. 
Sweet sorghums are varieties of Sorghum bicolor, which concentrate simple sugars in the stalks 
and have relatively smaller seed heads. They have been used traditionally for sugar and syrup 
production. Sweet sorghums has been identified as an ideal source for the sugars necessary for 
biofuel conversion. Sweet sorghum can be advantageous over cane sugar and corn because of 
reduced water requirements, shorter growing periods and reduced cultivation cost1. Sweet 
sorghum can grow in marginal lands, and therefore does not have to compete with land used for 
food production, as is the case with corn and sugar cane1,13. Sweet sorghum and other crops can 
be made more attractive for biofuel conversion when producers utilize the biorefinery approach. 
In this approach, the entire above ground portion of the plant is utilized in the creation of energy, 
reduction of waste streams, and production of value-added byproducts14,15, thereby reducing the 
costs associated with the generation of biofuels. Value-added by products could include 
bioactive extracts prepared for the purposes of human health.  
Our previous work on the bioactivity of sweet sorghum stalk components showed that dermal 
extracts were more potent in vitro against colon cancer stem cells, as compared to pith159. 
However, as the whole above ground portion of the plant will be available for the biorefinery 
approach, it is important to evaluate the bioactivity of extracts from different parts of the sweet 
sorghum plant in direct comparison with one another. Such information is currently understudied 
in sweet sorghums. In this study, the in vitro anticancer activities of pith, dermal, leaf and seed 
head from Dale and M81E sweet sorghum varieties harvested at four different stages during 
plant maturity were compared to understand the effects of time of harvest. Finally, the extent to 
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which sweet sorghum extract bioactivity is dependent on p53 status, and its capacity to suppress 
β-catenin and β-catenin’s downstream targets, cMyc, Survivin, and Cyclin D were investigated.  
3.3  Materials and Methods. 
3.3.1  Chemicals and Reagents. 
Sodium bicarbonate, monobasic sodium phosphate, dibasic sodium phosphate, and 
sodium chloride were purchased from Fisher Scientific (Pittsburgh, PA); potassium persulfate 
was purchased from Mallinckrodt chemicals (Hazelwood, MO); ABTS reagent, Folin-Ciocalteu 
reagent, Trolox, and gallic acid were purchased from Sigma (St. Louis, MO) for quantification of 
total phenolic and antioxidant activity.  
For cell culture experiments, 5-Fluorouracil (5-FU) was used as a positive control and 
procured from Sigma (St. Louis, MO); colon cancer stem cell media was obtained from 
Celprogen (San Pedro, CA). 
3.3.2 Sweet Sorghum Extraction. 
The sweet sorghum used in this study was generously provided by Great Valley Energy 
LLC (Bakersfield, CA). Dale and M81E were grown in Bakersfield, CA and harvested at 117, 
125, 138 and 152 d for dermal and 131, 145, 155, and 160 d for seed head. Later time points 
were chosen for seed head as maturation of this part of the plant occurs after stalk, based on 
sugar concentration. Samples included pith, dermal, leaf, seed head, and whole plant were 
mechanically separated and immediately frozen. Samples were shipped frozen overnight to Fort 
Collins, CO and then stored in -20 °C until needed. Two g of fresh sweet sorghum sample was 
extracted with 20 mL of 80% ethanol chilled to -20 °C to prevent excessive heating during the 
homogenization of sample. The mixture was then homogenized for 2 min using an IKA T25 
digital ultra TURRAX at 10 000 rpm. The extraction tubes were then vortexed for 1 min and the 
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resulting mixture was centrifuged at 4000 rpm for 5 min. The resulting pellet was then re-
extracted twice with 20 mL of extraction solvent. The filtrates were combined, filtered through 
0.45 micron hydrophilic PTFE syringe filters, and the final volume was made to 100 mL. 
Samples were then aliquoted and placed in -20 °C freezer until further analyzed. 
Phenolic enriched extracts were prepared by extracting two g sample in 20 mL of 80% 
ethanol chilled to -20 °C. Sample was homogenized with an IKA T25 Digital Ultra TURRAX set 
to 10 000 rpm for 2 min. The slurry was then mixed overnight on a reciprocal shaker under dark 
conditions and held at 4 °C. The mixture was then centrifuged and the supernatant was filtered 
with 0.45 µm PTFE filters (Tisch Scientific, North Bend, OH) into glass test tubes.  
Extracts were then further concentrated using nitrogen flow for approximately 10 h in a 35 °C 
water bath. The extracts were then quantified for total phenolics, aliquoted and stored in -80 °C 
until needed. For cell culture experiments, cells were dosed based on µg gallic acid equivalent 
per mL (µg GAE/mL). 
3.3.3 Quantification of Total Phenolics and Antioxidant Activity. 
Total phenolics were quantified by the Folin-Ciocalteu assay as described in Singleton’s 
work52 with minor modifications. Thirty-five µL of extract, standard or solvent was mixed with 
150 µL of 0.2 N Folin-Ciocalteu reagent in a 96-well plate. After mixing and incubating for 5 
min, 115 µL of 7.5% sodium bicarbonate was added, the contents mixed, and the plate was then 
incubated at 45 C for 30 min. The plate was allowed to cool for 1 h in dark conditions before 
absorbance at 765 nm was measured with a Biotek Synergy 2 plate reader (Winooski, VT). Data 




For quantification of antioxidant activity, the 2,2`-azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS) assay was performed as previously described6,146 with minor 
modifications. Briefly, ABTS working solution was prepared fresh by mixing 3 mM ABTS 
radical with 8 mM potassium persulfate and allowing this solution to react for at least 12 h in the 
dark before mixing with a pH 7.4 phosphate buffer to form the final solution. In triplicate, 10 µL 
of sample, standard, or solvent was added to individual wells of a 96-well plate followed by the 
addition of 290 µL of working ABTS solution. The resulting mixture was then mixed and 
allowed to react for 30 min before absorbance at 734 nm was measured using the aforementioned 
plate reader. The antioxidant activity was expressed as mean (n = 3) mg Trolox equivalents per g 
of sweet sorghum sample (mg TE/g) ± standard error.  
3.3.4 LC-MS Analysis. 
A Waters Acquity UPLC system fitted with a Waters Acquity UPLCT3 column (1.8 µM, 
1.0 X 100 mm) was used to achieve UPLC separation and a Waters Xevo G2 Q-Tof MS fitted 
with an electrospray source was used for accurate mass analysis. One µL of sample held at 5 °C 
was injected into the UPLC with 100% solvent A (water, 0.1% formic acid) and this was held for 
1 min. Next, a 12 min linear gradient to 95% solvent B (acetonitrile, 0.1% formic acid) was 
applied. The flow rate was maintained at a constant 200 µL/min and the column was maintained 
at a constant 50 °C for the entirety of the run. 
 Eluent from the UPLC was then infused into MS running in the positive ion mode, 
scanning from 50-1200 at a rate of 0.2 s/scan, alternating between MS and MSE mode. The 
collision energy was set to 6 V and 15-30 V for MS and MSE modes, respectively. Sodium 
formate was used to calibrate the equipment with mass accuracy within 1 ppm prior to the run. 
The capillary voltage was set to 2200 V, the source and the desolvation temperatures were set to 
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150 °C and 350 °C, respectively. The desolvation gas flow rate was 800 L/h of nitrogen. Waters 
raw data files were converted to .cdf format using Databridge software (Waters), and feature 
detection was performed using XCMS. Raw peaks were normalized to total ion signal in R. 
3.3.5 Cell Lines and Culturing Procedures. 
Colon cancer stem cells (CCSCs) were purchased from Celprogen (San Pedro, CA) and 
were maintained at a temperature of 37 °C and 5% CO2. CCSCs were maintained in colon cancer 
stem cell media (Celprogen) and passaged 1:10 to 1:20 when cells were 80% confluent. For 
experiments, CCSCs were treated in serum free colon cancer stem cell media (Celprogen) with 
sweet sorghum extracts based on µg GAE/mL in accordance with our previously published 
protocols160,161.  
3.3.6 Lentiviral shRNA Mediated Knockdown of p53 in CCSCs. 
Lentiviral particles encoding shRNA targeting p53 (Santa Cruz Biotechnology Inc; Santa 
Cruz, CA) were used to mediate p53 suppression in CCSCs at a multiplicity of 10 in growth 
medium containing 5 μg/mL polybrene. After 24 h of transfection, media was replaced and the 
cells were cultured for 2 d. Transfected cells were then selected in the presence of puromycin 
(7.5 μg/mL) for an additional 5 d. Western blots were then performed on transfected whole cell 
lysates to confirm the suppression of p53. 
3.3.7  Proliferation and Apoptosis. 
Cell proliferation was assessed via 5-bromo-2’-deoxyuridine (BrdU) assay (Cell 
Signaling Technology, Beverly, MA). Briefly, CCSCs were seeded in 96-well plates at 2 X 104 
cells per well. After 24 h incubation, the media was aspirated and the cells were treated with 
sweet sorghum extracts in triplicate with serum free media for 20 h at 37 °C. At the end of the 
treatment period, BrdU was added at a concentration of 10 µM per well to each well and 
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incubated at 37 °C for 4 h to allow incorporation of BrdU into cellular DNA resulting in 24 h 
total incubation. Media was then aspirated and the BrdU assay was performed according to 
manufacturer’s protocol. IC50 values were calculated and used to standardize dosage of dermal 
and seed head phenolics in subsequent studies of apoptosis. The annotations ½IC50, IC50 and 
2IC50 are used in Figures 21 and 22. This refers to ½, 1 and 2 times the IC50 value for each 
respective treatment in each respective cell lines. This equates to treatments of 5, 10 and 20 µg 
GAE/mL for a treatment with an IC50 of 10 µg GAE/mL in a particular cell line. 
Apoptosis was analyzed by measuring active caspases 3 and 7 with a Caspase-Glo 3/7 
assay kit (PromegaCorp., Madison, WI) and by assessing DNA fragmentation with the terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method. For measuring caspase 
activity, cells were treated for 12 or 24 h with treatments. Then cells were trypsinized and 200 
µL of media containing CCSCs or CCSCs p53 shRNA were transferred into a white 96-well 
plate and caspase activity was measured according to manufacturer’s protocol. Data were 
normalized to cell count and expressed as percent of solvent control. For TUNEL assay, cells 
were seeded into four-well chambered glass slides at a density of 1 X 105 cells per chamber. 
After treatments with control compounds and sweet sorghum extracts, the slides were prepared 
and analyzed for TUNEL staining according to manufacturer’s protocols (In Situ Cell Detection 
Kit, FL: Roche Diagnostics; Mannheim, Germany).  
3.3.8  Western Blotting. 
 Cells were plated in six-well plates at a concentration of 3.0 X 105 cells per well in 
human colon cancer stem cell medium. After 24 h, cells were treated in serum free medium for 
18 h. Cells were then mixed in 150 µL/well high salt buffer (50 mM HEPES, 0.5 M NaCl, 1.5 
mM MgCl2, 1 mM EGTA, 10 % Glycerol, 1 % Triton-X, pH 7.5) containing protease inhibitors 
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(Thermo Scientific; Rockford, IL) and lysed using sonication. Protein (40 µg) was then subjected 
to gel electrophoresis on Criterion XT Bis-Tris 4 - 12 % Gel (Biorad; Hercules, CA) and 
transferred to PVDC membrane. The membrane was blocked using Superblock (Thermo 
Scientific; Rockford, IL) overnight at 4 °C. The antibody against PARP (9542p) was purchased 
from Cell Signaling Technologies (San Diego, CA). Antibodies against β-actin (sc-1616), p53 
(sc-6243), β-catenin (sc-7963), survivin (sc-17779), cyclin D1 (sc-20044), cMyc (sc-40), GSK-
3β (sc-9166), pGSK-3βS9 (sc-11757), and pGSK-3βY219 (sc-135653) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). All primary antibodies were incubated overnight at 4 °C 
at a dilution of 1:500. IRDye 800 Donkey anti-goat, IRDye 680 goat anti-mouse, IRDye 800 goat 
anti-mouse, IRDye 680 goat anti-rabbit, and IRDye 800 goat anti-rabbit secondary antibodies 
were purchased from LI-COR Bioscience (Lincoln, NE) and incubated for 2 h at room 
temperature at a dilution of 1:10000. Blots were imaged and quantified using the Odyssey 
Infrared Imaging System and software (LI-COR Biotechnology; Lincoln, NE). 
3.3.9  Statistical Analysis. 
 Statistical analysis was done using SAS version 9.3 and significance was determined by 
one way ANOVA, followed by the post-hoc Fisher least significant difference (LSD) test for 
multiple means comparisons. For Western blotting, data were transformed by natural log before 
being subjected to one way ANOVA and LSD statistical analyses. Pearson’s correlations were 
performed using IBM’s SPSS version 21. Values not sharing the same letter were statistically 






3.4 Results and Discussion. 
3.4.1 Component Analysis Reveals Seed Head and Dermal as Most Potent Sources of 
Anticancer Phenolics from Sweet Sorghum. 
 Data for the TP and ABTS values of pith, dermal, leaf, seed head and whole plant 
components from the sweet sorghum variety M81E are summarized in Figure 19A. We observed 
that the leaf and seed head had significantly higher TP with values of 4.45 and 4.37 mg GAE/g, 
respectively (P < 0.05). Dermal and the whole plant had similar levels of TP, 1.07 and 1.17 mg 
GAE/g, respectively. However, this was not significantly different than pith (0.14 mg GAE/g) at 
the 5% level. Similar findings were found for the ABTS values of sweet sorghum components. 
ABTS values for leaf and seed head were the highest at 16.98 and 19.18 mg TE/g, respectively. 
The dermal (7.31 mg TE/g) and the whole plant (7.64 mg TE/g) had significantly higher ABTS 
than the pith at 0.35 mg TE/g (P < 0.05). Our findings are similar to the findings of Awika et al. 
who reported TP and ABTS values for sorghum grains to range from 1 - 13 mg GAE/g and 1.5 - 
27 mg TE/g (6 - 108 µMole TE/g) on a dry matter basis, respectively6. Ring et al. investigated 
the levels of phenolics in different grain sorghum tissues during maturation and reported similar 
TP values for the leaves (3.4 – 11.7 mg GAE/g) and stalk (0.6 – 1.0 mg GAE/g)56. This indicates 
there is a similarity in the quantities of TP and other reducing agents expressed in sweet 
sorghums and grain sorghums, despite the high morphologic and phenotypic variation. 
 The antiproliferative and proapoptotic properties of these extracts in vitro against CCSCs 
were investigated, and the data are summarized in Figures 19B-D. Due to the low concentration 
of phenolics and our previous findings suggesting lack of in vitro bioactivity159, pith extract was 
excluded from this analysis. Dermal and seed head extract suppressed proliferation at 35 µg 





Figure 19. Extracts prepared from sweet sorghum variety M81E components (pith, dermal, leaf, 
seed head, and whole plant) contain total phenolics and antioxidants with antiproliferative and 
proapoptotic activity. (A) The total phenolics and ABTS values of sweet sorghum components as 
measured by the Folin-Ciocalteu and ABTS assay, respectively. Values are presented in mg gallic 
acid equivalents per g of tissue and mg Trolox equivalents per g of tissue (collectively referred as 
mg/g) for total phenolics and ABTS, respectively. Mean mg/g values (n = 3) ± standard error are 
represented. (B) The antiproliferative activity of sweet sorghum component extracts after 24 h 
treatment with 35 µg GAE/mL, as measured by the BrdU assay. Data are presented as percent of 
control (% control) as means (n = 3) ± standard error. Sweet sorghum component extracts induce 
effector caspase activation and DNA fragmentation after 24 h treatment with 35 µg GAE/mL, as 
measured by (C) Caspase 3/7 Glo assay and (D) TUNEL assay. Data for Caspase 3/7 Glo assay 
are presented as percent of control as means (n = 2) ± standard deviation. Data for TUNEL assay 
are presented as mean (n = 2) apoptotic index (percent positive cells) ± standard deviation. 
Different letters indicate significant differences (P < 0.05) among treatments. Control = 80% 
ethanol used as negative control. 
 
significantly more than leaf (78%) or whole plant extract (73%) (P < 0.05). Proapoptotic activity 
of the extracts was measured by the Caspase 3/7 Glo assay and TUNEL assay. Dermal extracts 
were more potent in activating caspases (610%), as compared to other components and whole 
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plant (Figure 19C). Leaf, seed head, and whole plant extracts all induced caspase activation to 
similar levels in comparison to control (274%, 336%, and 255%, respectively). Interestingly, 
only extracts from dermal and seed head increased the percentage of apoptotic cells as measured 
by the TUNEL assay to 57% and 49%, respectively (P < 0.05). Based on the observed difference 
in the proapoptotic effects of dermal and seed extracts in comparison to other components, these 
components were selected for further investigations. Despite high TP and ABTS values, leaf 
extract only marginally decreased CCSCs proliferation and failed to increase apoptosis as 
measure by TUNEL positive staining. It is important to note that these extracts did increase 
activated caspases 3 and 7 after 12 h and likely that with time would have resulted in DNA 
cleavage observable by TUNEL staining. 
3.4.2 Effects of Time of Harvest on the Bioactivity of Sweet Sorghum Components. 
The time of harvest has been shown to influence levels of bioactive compounds in 
sorghum162,163. We wanted to know if this variable had an influence on the levels and bioactivity 
of sweet sorghum. Table 9 shows TP, ABTS and BrdU values from the dermal and seed head of 
Dale and M81E sweet sorghum varieties at four times of harvest to assess the impact of plant 
development on the quantities and activity of dermal and seed head phenolic rich extracts. The 
TP and ABTS values for both dermal and seed head were similar in all varieties. For dermal, TP 
and ABTS values ranged from 0.84 – 2.14 mg GAE/g and from 2.32 – 6.48 mg TE/g for dermal 
across all varieties, respectively. In agreement with the component analysis, the seed head had 
higher TP and ABTS values than did dermal, indicating that the seed head of sweet sorghum is a 
more concentrated source of phenolics. Seed head TP and ABTS values ranged from 2.28 – 8.88 




Table 9. Determination of TP, ABTS and BrdU in dermal and seed head extracts from Dale and M81E varieties of 
sweet sorghum at different times of harvest. 
 dermal  seed head 
variety DAP a TPb ABTSc BrdUd  DAP TP ABTS BrdU 
Dale 117* 0.84 ± 0.04 2.32 ± 0.17   59 ± 3.5  131** 2.30  ± 0.23 13.03 ± 0.94 32 ± 3.0 
 125* 1.10 ± 0.01 3.18 ± 0.09 120 ± 2.8  145** 2.46 ± 0.11 13.93 ± 0.35 26 ± 2.3 
 138* 1.42 ± 0.09 3.85 ± 0.32 109 ± 1.3  153** 2.28 ± 0.03 12.64 ± 0.58 49 ± 2.3 
 152* 1.48 ± 0.14 4.11 ± 0.59 109 ± 1.6  160** 2.82 ± 0.25 14.97 ± 0.72 79 ± 1.0 
M81E 117* 1.52 ± 0.06 4.68 ± 0.31 72 ± 1.2  131** 6.01 ± 0.38 25.58 ± 1.23 15 ± 0.5 
 125* 1.86 ± 0.08 5.32 ± 0.16 54 ± 2.1  145** 5.00 ± 0.32 21.57 ± 1.22 13 ± 0.4 
 138* 2.14 ± 0.14 6.38 ± 0.55 33 ± 4.7  153** 8.02 ± 0.23 28.98 ± 0.32   2 ± 0.3 
 152* 2.10 ± 0.04 6.48 ± 0.28 91 ± 0.9  160** 8.88 ± 0.46 28.65 ± 0.07   5 ± 0.6 
a DAP = Days after planting. Sweet sorghums were harvested at different times represented as d after planting. * 
Were planted on 05/10/2012. ** Were planted on 06/13/2012. bTotal phenolics (TP) were determined by the 
Folin-Ciocalteu assay and data are presented as mg gallic acid equivalents per g sample (mg GAE/g). cABTS 
values were determined by the ABTS method and data are presented as mg Trolox equivalents per g sample (mg 
GAE/g). dCCSCs were treated for 24 h with dermal or seed head extracts at 35 µg GAE/mL concentration. Values 
were determined from the BrdU assay and expressed as percent of control. Low values indicate proliferation 
suppression. All data are presented as means (n = 3) ± standard error. Highlighted cells were selected for 
subsequent investigations.  
 
in agreement with previous works on sorghum6,54, there was a high correlation between sweet 
sorghum TP and ABTS values of both dermal (r = 0.966, P < 0.0005) and seed head (r = 0.974, P 
< 0.0005). Furthermore, time of harvest correlated with dermal TP (r = 0.476, P = 0.019) and 
ABTS values (r = 0.531, P = 0.008). This indicates that as the sweet sorghum plant matures, it 
concentrates phenolics and antioxidants in the dermal layer of the stem.   
One of the most important roles of phenolics in plants is to defend the plant from 
pathogenic infection and to deter herbivorous predation50. Therefore it is logical for sweet 
sorghum to concentrate more phenolics in the seed head than dermal layer as a means of 
preserving its genome. Indeed, certain bird resistant varieties of grain sorghum have been 
identified, and these varieties differ based on the presence of tannins, a broad class of astringent 
polyphenolics, which deter feeding164,165. As sweet sorghums mature, sugars are concentrated in 
the stalk and this puts the plant at risk for boring insects. Thus, it is logical for the plant to 
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concentrate phenolics during plant development to prevent and protect the plant from attack.  
The antiproliferative activity varied widely amongst varieties and time of harvest in sweet 
sorghum dermal and seed head components. We found significant negative correlations between 
seed head BrdU antiproliferative values and seed head TP (r = -0.716, P < 0.0005) and ABTS (r 
= -0.726, P < 0.0005) values. This may reflect changing bioactive profiles in the seed head and 
warrants further investigation. For dermal extracts, BrdU antiproliferative activity did not 
correlate with time of harvest, TP values, nor ABTS values, implying that the antiproliferative 
activity of these extracts cannot be explained by quantity of the phenolics in the plant and may 
be better explained by the composition of the phenolics at the time of harvest. One confounding 
factor may be differences in non-bioactive reducing, as these can contribute to TP and ABTS 
readings without contributing to antiproliferative activity of the extract. Nonetheless, our 
analysis shows extracts from multiple varieties of sweet sorghum dermal and seed head, 
harvested at various stages of maturity, contain strong antiproliferative constituents. This 
supports the use of dermal and seed head as a source of bioactive compounds for human health 
in the biorefinery approach to biofuel conversion from sweet sorghum. This is important as 
variety and time of harvest may vary between seasons and between producers. 
3.4.3 The Anticancer Effects of Dermal and Seed Head Phenolics  
To better understand the antiproliferative and proapoptotic effects of sweet sorghum 
phenolics, and to determine the extent to which these effects are p53-dependent, successive 
studies were performed. The highlighted rows in Table 9 indicate the source of phenolic rich 
extracts to be used in subsequent studies of proliferation and apoptosis. These materials were 
selected based primarily on the ability of the extract to decrease proliferation as measured by 
BrdU assay. We then compared observed bioactivities of sweet sorghum extracts with the 
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standard chemotherapeutic drug 5-FU. As shown in Figure 20, IC50 values were calculated by 
BrdU assay after 24 h treatment in CCSCs and CCSCs p53 shRNA. Both dermal and seed head 
dose-dependently decreased cellular proliferation in both cell lines. Dermal extract had IC50 
values of 25 and 36 µg GAE/mL in CCSCs and CCSCs p53 shRNA, respectively. Seed head 
extracts were shown to be more potent than dermal and independent of p53 as treatment resulted 
in IC50 values of 10 µg GAE/mL in both cell lines with no statistical differences observed 
between cell lines. However, in CCSCs p53 shRNA, seed head extracts suppressed proliferation 
in a p53 independent fashion, whereas the dermal extract was not as effective in the p53 shRNA 
cell line and this was reflected by a higher IC50 for dermal extract. Interestingly, we observed 5-
FU induced increases in rates of proliferation in CCSCs and CCSCs p53 shRNA. This is in  
 
Figure 20. The antiproliferative activity of select dermal and seed head extracts and calculated 
IC50 values were determined by BrdU assay after 24 h treatment with extracts. Data are presented 
as percent of control as means (n = 3) ± standard error. * Significant difference from control (P < 
0.05). † Significant differences between CCSCs and CCSCs p53 shRNA of the same treatment (P 
< 0.05). Control = 80% ethanol used for solvent control; D = Dermal treatments at concentrations 
indicated by number in μg GAE/mL; SH = Seed head extract treatments at concentrations indicated 




contrast to previous studies reporting decreases in the proliferation of multiple colon cancer cell 
lines166,167. However, it has been reported that ATP synthase inhibitors in conjunction with 5-FU 
treatment increased colon cancer cell proliferation168. 
The proapopototic activity of sweet sorghum extracts are summarized in Figure 21 and 
assessed by activation of effector caspases with Caspase 3/7 Glo assay, PARP cleavage by 
Western blotting, and apoptotic index with TUNEL staining (% TUNEL positive staining). 
Dermal extracts, only after 18 h, significantly increase the levels of cleaved PARP by 7.8-fold 
and 2.1-fold in CCSCs and CCSCs p53 shRNA, respectively. Furthermore, dermal extract at 2 
times the IC50 concentration increased the percentage of TUNEL positive CCSCs and CCSCs 
p53 shRNA to 82% and 45%, respectively. Therefore, the proapoptotic effects observed in 
dermal treated cells was most probably mediated via activated caspases as activated effector 
caspases are responsible for PARP cleavage. Given the increase in caspase activity observed in 
dermal treated cells after 24 h (Figure 19C), it may be that activation of effector caspases comes 
after the 12 h time point we measured for this analysis. Our results further show the activity of 
dermal extract was markedly and significantly diminished by suppression of the tumor 
suppressor p53 in CCSCs p53 shRNA, indicating a partial dependence on p53 for the mediation 
of dermal extract’s activity. This was not observed in cells treated with seed head extract. After 
12 h of seed head treatment, caspase activation was increased from 100% to 5118% control and 
from 100% to 4503% of control in CCSCs and CCSCs p53 shRNA, respectively. There was no 
difference between cell lines in caspase activation, indicating a p53-independence. Interestingly, 
this surpassed caspase activation induced by 5-FU. Seed head treatment resulted in 4.7-fold and 
1.3-fold decreases in full length PARP and 21-fold and 38-fold increases in the 82 kDa PARP 




Figure 21. Extracts from sweet sorghum dermal and seed head induce effector caspases-3 and -7 activity, 
PARP cleavage, and DNA fragmentation, as measured by Caspase 3/7 Glo assay, Western blotting, and 
TUNEL assay in Colon Cancer Stem Cells (CCSCs). (A) Data from Caspase 3/7 Glo assay are presented 
as percent of the solvent control (% Control) as means (n = 2) ± standard deviation. (B) Images from 
Western blots probed with antibodies against PARP and β-actin. (C) Levels of PARP and cleaved PARP 
were quantified by densitometry relative to β-actin with control lanes set to 1. (D) Results from TUNEL 
assay experiments are presented at apoptotic index (% Postive Cells) as means (n = 2) ± standard deviation. 
(E) Representative images of TUNEL staining in cells treated with control, dermal or seed head treatments 
at their respective IC50 values. Images from top row are from CCSCs and bottom row are from CCSCs p53 
shRNA. * Indicates significant difference from control (P < 0.05). † Indicates significant differences 
between CCSCs and CCSCs p53 shRNA of the same treatment (P < 0.05). The coefficient preceding the 
treatment represents dose (i.e. 1/2 is equivalent to 1/2 of the IC50 value) Control = 80% ethanol used for 
solvent control; D = Dermal extract; SH = Seed head extract; 5FU = 5-fluorouracil (18 µg/mL).  
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indicated apoptosis after 18 h of seed head treatment, as seed head increased the percentage of 
TUNEL positive CCSCs to 88% and to 64% in CCSCs p53 shRNA at a concentration of 2 times 
the IC50. 
3.4.4 Dermal and Seed head Suppresses β-Catenin Levels and Downstream Targets. 
 Having shown differences in the dependence of p53 status for the activity of dermal and 
seed head extracts, successive investigations were carried out to assess the molecular 
mechanisms responsible for the activities observed in sweet sorghum phenolics. Given the 
prominence of aberrant Wnt/β-catenin in colon cancer, we treated CCSCs and CCSCs p53 
shRNA with dermal and seed head phenolics for 18 h and Western blotting was performed to 
measure protein expression. Figure 22 demonstrates treatment with seed head decreased β-
catenin in a dose-dependent manner in both CCSCs and CCSCs p53 shRNA. However, this 
activity was slightly diminished in the p53 shRNA cell line, indicating a need of p53 for full 
activity. Dermal phenolics also decreased β-catenin levels in CCSCs. However, this activity was 
completely absent in p53 shRNA cells, indicating p53-dependency.  
 β-catenin’s prosurvival effects are partly mediated via the transactivation of target genes, 
such as cMyc, Cyclin D1, and Survivin123. In accordance with our observations, seed head 
treatment of both cell types resulted in concurrent decreases in cMyc and Survivin in a partly 
p53-independent manner. Dermal treatment also resulted in the decrease of these β-catenin 
targets in CCSCs. However, dermal activity was diminished in CCSCs p53 shRNA and 
determined to be p53-dependent. The only exception to this was Cyclin D1. Dermal significantly 
and dose dependently suppressed Cyclin D1 levels in both cell lines, indicating that Dermal’s 
effects on Cyclin D1 are p53-independent. Furthermore, this indicates that suppression of Cyclin 





Figure 22. Extracts from sweet sorghum dermal and seed head decrease levels of β-catenin and β-catenin targets cMyc, Cyclin D1, and 
Survivin in a p53-dependent manner for dermal treated cells and a partial p53-dependent manner for seed head treated Colon Cancer 
Stem Cells (CCSCs). (A) CCSCs and CCSCs p53 shRNA were treated with dermal or seed head extracts for 18 h and whole cell lysates 
were subjected to Western blotting and probed with antibodies against GSK-3β, pGSK-3βS9, pGSK-3βY216, β-catenin, cMyc, Cyclin D1, 
Survivin, and β-actin. (B) Levels of β-catenin, cMyc, Cyclin D1, and Survivin were quantified by densitometry relative to β-actin with 
control lanes set to1. Data are presented as means (n = 2) ± standard deviation. * Indicates significant difference from control (P < 0.05). 
† Indicates significant differences between CCSCs and CCSCs p53 shRNA of the same treatment (P < 0.05). Control (C) = 80% ethanol 
used for solvent control; D = Dermal extract treatments; SH = Seed head extract treatments. Dermal and seed head treatments were 
dosed based on IC50 values in μg GAE/mL. The coefficient preceding the treatment represents dose (i.e. 1/2 is equivalent to 1/2 of the 
IC50 value). 5FU = 5-fluorouracil (18 µg/mL).
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apoptosis (TUNEL staining) and β-catenin (r = -0.920, P < 0.01), cMyc (r = -0.922, P < 0.01), 
and Survivin (r = -0.519, P < 0.01). We did not find significant correlations between apoptosis 
and Cyclin D1, which is to be expected as it functions to suppress cell cycle progression and is 
not thought to influence apoptosis.  
GSK-3β, pGSK-3βS9 and pGSK-3βY219 were probed with Western blotting to determine if 
β-catenin decreases in response to treatment were a result of altered GSK-3β activity. Figure 22a 
shows that while GSK-3β, and pGSK-3βS9 levels remained unaltered, levels of pGSK-
3βY219decreased in CCSCs. This is contrary to expectation, as decreased levels of active pGSK-
3βY219would seemingly increase β-catenin. However, decreases in β-catenin levels could be 
explained by enhanced binding of GSK-3β to β-catenin through interaction with APC. As this 
was not measured in the current study, this will remain purely as speculation. Nonetheless, we 
show for the first time that sweet sorghum extracts dose-dependently decreased β-catenin levels, 
and this was concurrently associated with decreased cellular proliferation, increased apoptosis, 
and decreased expression of cMyc, Cyclin D1 and Survivin. This was found to be partly p53-
independent in seed head extract and p53-dependent in dermal extract. 
Differences observed in LC-MS anlaysis may explain differences in proapoptotic and 
antiproliferative activity observed between dermal and seed head, demonstrating that the 
composition of phenolics as determined by source is an important determinant of an extract’s 
effectiveness against cancer stem cells and dependence on p53 for activity. These bioactive 
compounds contained within the seed head extract and dermal extract of sweet sorghum possess 
antiproliferative and proapoptotic activity against colon cancer stem cells in a partial p53-
dependent manner for seed head extracts and p53-dependent for dermal extracts. Apoptosis was 
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mediated via activation of effector caspases, resulting in activation of PARP and subsequent 
DNA fragmentation. 
To better understand the differences observed in dermal’s and seed head’s in vitro 
activity, we next performed LC-MS analysis to assess differences in polyphenolics. Analysis 
revealed 842 different features that differed by at least 2-fold (Figure 23) (P < 0.05). We were 
also able to identify differences in multiple phenolic compounds previously reported in sweet 
sorghum and reported to have bioactivity (Table 10). In total, we identified 10 compounds; 
apigeninidin, luteolinidin, malvidin glucoside, apigenin, luteolin, naringenin, naringenin 
glucoside, eriodictyol glucoside, taxifolin, and catechin. Based on relative abundance, seed head 
contained 9813% more apigeninidin and 650% more luteolininidin, a class of 3-
deoxyanthocyanidins with potent phase II enzyme inducing and anticancer activity8. Seed head 
also contained significantly more luteolin, apigenin, naringenin glucoside, and Eriodictyol 
glucoside.  
Table 10. Phenolic compounds detected by LC-MS in dermal and seed head extracts. 











apigeninidin C15H11O4+ 4.26 255.066 255.0660M 0 29 2875* 4,5,70 
luteolinidin C15H11O5+ 5.97 271.061 271.0607M 1 6 45* 4,5,70 
malvidin 3-O-
glucoside 
C23H25O12+ 4.83 493.134 493.1314M 5 221* 91 4 
apigenin C15H10O5 4.02 271.061 271.0607 1 41 5934* 5 
luteolin C15H10O6 3.37 287.056 287.0556 1 12 162* 5,72 
naringenin 




















C21H22O11 4.28 451.123 451.124 2 10 464* 79 
taxifolin C15H12O7 3.37 305.066 305.0662 1 188* 34 5 
catechin C15H14O6 4.07 291.086 291.0869 3 7 86* 5 
aFormulas are based on [M]. bExact masses are based on [M+H]+ unless otherwise indicated. MMass based on 
[M]+. cNormalized peak intensities based on peak areas normalized to total ion signal in R. dReferences which 
have previously identified the compound listed. * Significant differences (P < 0.05) observed between dermal 




Interestingly, luteolin and apigenin have demonstrated proapoptotic activity in the p53 
mutated colon cancer HT29 cell line170,171. This supports our observations of p53-independent 
apoptosis in seed head treated CCSCs. On the other hand, the dermal layer contained more of the 
malvidin glucoside, naringenin and taxifolin as compared to seed head. These differences 
observed in LC-MS anlaysis may explain differences in proapoptotic and antiproliferative 
activity observed between dermal and seed head, demonstrating that the composition of 
phenolics as determined by source is an important determinant of an extract’s effectiveness 
against cancer stem cells and dependence on p53 for activity.  
 
Figure 23. Extracts from the dermal and seed head extract differed in metabolomics profiling. 
Volcano plot illustrating different features between dermal and seed head extracts. log2 fold change 
(seed head/dermal) is plotted on X-axis against the –log10 Pvalue. Features greater than 2-fold 
change between seed head and dermal are represented by points that fall outside of the vertical 
bars. Significantly different features (P < 0.05) are those features that fall above the horizontal bar.  
 
 The cumulative results from this study suggest that the phenolics of sweet sorghum 
component dermal and seed head have antiproliferative and proapoptotic activity. Seed head and 
dermal extracts were the most potent, while leaf and stalk pith were least effective. 
Antiproliferative effects of seed head and dermal were p53-independent and partially p53-
dependent, respectively. Proapoptotic effects were partially p53-dependent for both extracts. 
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Proapoptotic activity tracked closely with altered β-catenin levels, which resulted in decreased 
proliferative and survival signaling by way of decreased cMyc, cyclin D1, and survivin 
expression (Figure 22). Differences in composition of phenolic compounds contained in the 
dermal and seed head may help to explain differences in anticancer effects. A complete 
understanding of the mechanism(s) of action is still unknown and further research is needed to 
elucidate sweet sorghum’s anticancer properties and potential uses as a chemopreventive and 
chemotherapeutic agent in vivo. Furthermore, research is needed to understand the mechanisms 
through which these extracts suppress β-catenin. While serving as a feedstock for biofuel 
production, sweet sorghum biomass generated by biorefining may also serve as a reservoir for 




CHAPTER 4: PHENOLIC RICH EXTRACTS FROM THE DERMAL LAYER OF 
SWEET SORGHUM (SORGHUM BICOLOR) STALK, A BYPRODUCT OF BIOFUEL 
PRODUCTION, REDUCES SYSTEMIC OXIDATIVE STRESS IN A MURINE MODEL 





Obesity is now a major global health problem and is often associated with chronic, sub-acute 
inflammation and increased oxidative stress. Sorghum bicolor is an important agricultural crop 
and the grain, bran, leaves, and leaf sheaths contain phenolic acids, anthocyanidins, 
anthocyanins, and other flavonoids with antiinflammatory and antioxidant activities. However, 
less has been documented on the in vivo safety and bioactivity of S. bicolor stalk. The protective 
effects of an ethanolic extract from the dermal layer of the stalk (SS) were examined in male and 
female mice consuming low-fat diet (LFD) and high-fat diet (HFD). Extract was supplied as a 
lyophilized powder in the diets at 1% w/w. During the last week, mice were subjected to dual 
energy x-ray absorptiometry and glucose tolerance test to assess adiposity and metabolic 
disorder, respectively. After 10 wk of feeding, mice were sacrificed, vital organs weighed, and 
tissues and plasma collected for further analysis. The inflammatory markers, tumor necrosis 
factor  (TNF), interleukin-6 (IL-6), and IL-1β, the macrophage marker, F4/80, and monocyte 
chemotactant protein 1 (MCP-1), and the tight junction proteins zona occluden 1 (ZO-1) and 
occludin were assessed in the colonic mucosa by qPCR. SS was well-tolerated by mice 
consuming LFD and HFD, as indicated by normal body weight, vital organ weights, feed intake, 
and water intake. Addition of SS had no effects on adiposity. SS did suppress oxidative stress as 
indicated by reduced plasma 8-isoprostane levels. These results support S. bicolor stalk as a safe 
source of bioactive compounds with in vivo antioxidant activity.  




 Obesity is now a major global health problem172. Obesity is often associated with 
chronic, sub-acute inflammation and increased oxidative stress173. Indeed, inflammation and 
oxidative stress is now recognized as an emerging feature of the metabolic syndrome174 and is 
thought to play a causal role in insulin resistance175. Furthermore, obesity is linked to an 
increased risk for many chronic diseases such as cardiovascular disease and cancer36,176. Obesity 
has been linked to colon cancer, which is promoted by altered inflammation, oxidative stress, 
and endocrine signaling that accompanies obesity36.  
 In rodent models of high-fat diet induced obesity, bioactive compounds have 
demonstrated antiinflammatory and antioxidant properties177,178. Sorghum bicolor is an 
agriculturally important cereal crop, placing fifth in worldwide cereal production1. Furthermore, 
it has been used in traditional medicines for the treatment of many disease states3. Recent 
investigations have elucidated some antiinflammatory and antioxidant activities of S. bicolor 
extracts in vitro and in vivo179–181. Sweet sorghums are varieties of S. bicolor, which concentrate 
simple sugars in the stalk, and as a result, have larger thicker stalks with smaller seed heads. S. 
bicolor grains, bran, leaves, and leaf sheaths have also been shown to contain phenolic acids, 
anthocyanidins, anthocyanins, and other flavonoids with bioactivity4,5,7,62,67,70,82. These have been 
reported in the grain, leaves, and leaf sheathes (also known as leaf base). Sorghum leaf base 
extracts have demonstrated in vitro antiinflammatory181 and in vivo antioxidant activity182. 
However, antioxidant and antiinflammatory properties of the stalk have not been well 
characterized. In this study, we used a high-fat diet to induce obesity in male and female mice 
and investigated the antioxidant and antiinflammatory effects of oral administration of sweet 




4.3 Materials and Methods. 
4.3.1 Sweet Sorghum Extraction. 
 Sweet sorghum dermal raw material was generously provided by Great Valley Energy 
LLC (Bakersfield, CA). Extract from this material was prepared by homogenizing approximately 
1 kg dermal material in 80% ethanol (1:10) chilled to -20 °C to prevent excess heating with an 
IKA T25 Digital Ultra TURRAX set to 10 000 rpm. The resulting slurry was then gravity filtered 
with coffee filters to remove particulates in dark conditions. The resulting extract was dried 
under nitrogen flow at 35 °C for 24 h to remove ethanol. The aqueous portion was then frozen 
and lyophilized (Virtis Genesis 25LL; Gardiner, NY) into a powder. 
4.3.2 Animal Care and Treatment. 
 Male and Female A/J mice from Jackson Laboratory (Bar Harbor, Maine) were housed 4 
or 5 animals per cage in the controlled conditions of a constant 22 °C temperature, 12 h 
light/dark cycles, and free access to food and water. Seventeen male and seventeen female three-
week-old mice were randomly assigned by gender and weight into one of five dietary treatment 
groups. These treatments were low-fat diet (LFD: n = 8; 4 males and 4 females), low-fat diet plus 
1% sweet sorghum dermal layer extract (LFD + SS: n = 9; 4 males and 5 females), high-fat diet 
(HFD:  n = 8; 4 males and 4 females), and HFD plus 1% SS (HFD + SS: n = 9; 5 males and 4 
females). LFD was prepared entirely of the standard AIN-93G rodent chow. HFD was a 
westernized diet consisting of 40% kcal from dietary fat. Diets containing 1% SS had equivalent 
amounts of corn starch displaced in the diets by presence of dried extracts on a per weight basis. 
The 1% diet was chosen based on toxicity studies of rodents consuming extracts of sorghum leaf 
base183. At this level, a mouse weighing 25 g and consuming 5 g diet per d would not receive 
more than 2000 mg/kg/d of diet. All diets were prepared by Harlan Tekland (Madison, WI) and 
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are outlined in Table 11. All animal experimental protocols were approved by the Institutional 
Animal Care and Use Committee of Colorado State University. 
Table 11. Composition of control and experimental diets. 
ingredients (%) LFD LFD + SS HFD HFD + SS 
sweet sorghum dermal extract 0.0 1.0 0.0 1.0 
casein 20.0 20.0 19.5 19.5 
L-cysteine 0.3 0.3 0.3 0.3 
sucrose 10.0 10.0 26.1 26.1 
maltodextrin 13.2 13.2 7.5 7.5 
corn starch 39.8 38.5 21.1 20.1 
cellulose 5.0 5.0 2.0 2.0 
soybean oil 7.0 7.0 0.0 0.0 
anhydrous milkfat 0.0 0.0 5.5 5.5 
lard 0.0 0.0 2.0 2.0 
beef tallow 0.0 0.0 3.5 3.5 
corn oil 0.0 0.0 5.5 5.5 
peanut oil 0.0 0.0 1.0 1.0 
hydrogenated vegetable shortening 0.0 0.0 2.5 2.5 
vitamin and mineral mix (low Ca, high P) 4.5 4.5 3.5 3.5 
fatty acid composition (%) LFD LFD + SS HFD HFD + SS 
PUFA 3.78 3.78 4.44 4.44 
MUFA 1.54 1.54 7.68 7.68 
SFA 1.05 1.05 8.08 8.08 
LFD = Low-fat diet control; HFD = High-fat diet control; LFD + SS = LFD with sweet sorghum dermal 
layer extract; HFD + SS = HFD with sweet sorghum dermal layer extract; PUFA = Polyunsaturated 
fatty acids; MUFA = Monounsaturated fatty acids; SFA = Saturated fatty acids. 
 
4.3.3 Glucose Tolerance Test. 
 The glucose tolerance test were performed using recommendations from184. Mice were 
fasted for 6 h before a solution of 50% glucose was injected intraperitoneally at 2 g/kg 
bodyweight. Blood samples were collected from the tail vein and measured with glucometer at 0, 
15, 30, 60 and 120 min. Blood glucose measurements were then plotted and the area under the 
curve (AUC) was calculated in Microsoft Excel. Data are expressed as mean AUC ± standard 
error. 
4.3.4 Body Weight and Dual Energy X-Ray Absorptiometry. 
 Body weights were measured weekly. Percentage body fat was assessed by dual energy 
x-ray absorptiometry (DEXA) scan at wk 9 of the study. Mice were anesthetized under 
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isoflurane during the scanning procedure. Each animal was scanned in triplicate and data 
presented as mean percentages body fat ± standard error. Fat mass was calculated by multiplying 
the bodyweight of animal (g) to the percentage body fat and is presented as mean fat mass ± 
standard error. 
4.3.5 RNA Extraction and Quantitative Real Time PCR. 
 RNA was isolated using the TRIzol method (Invitrogen, Carlsbad CA). cDNA was 
generated using qScript cDNA Supermix (Quanta Biosciences; Gaithersburg, MD) according to 
manufacturer’s protocol. Real-time qPCR was performed on the Eco Real Time PCR System 
(Illumina; San Diego, CA). All primers were purchased from Fisher Scientific (Pittsburg, PA) 
and the sequences are outlined in Table 12. The relative expression of each gene was normalized 
to β-actin. A mixture of the cDNA from all samples was used as the calibrator to which all other 
groups were compared using the ΔΔCq method. All values are expressed as mean fold change ± 
standard error compared to LFD control.  








β-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 154 
TNFα CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 61 
NF-κB ATGGCAGACGATGATCCCTAC TGTTGACAGTGGTATTTCTGGTG 111 
TLR4 ATGGCATGGCTTACACCACC GAGGCCAATTTTGTCTCCACA 129 
IL-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 89 
IL-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 76 
MCP-1 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 121 
F4/80 TGACTCACCTTGTGGTCCTAA CTTCCCAGAATCCAGTCTTTCC 111 
Occludin TTGAAAGTCCACCTCCTTACAGA CCGGATAAAAAGAGTACGCTGG 129 
ZO-1 GCCGCTAAGAGCACAGCAA TCCCCACTCTGAAAATGAGGA 134 
 
4.3.6 Sample Collection. 
  Animals were euthanized by cardiac puncture and cervical dislocation under isoflurane 
anesthesia. Blood was collected in heparin laden tubes and immediately centrifuged at 4 °C to 
collect plasma. Plasma samples were then aliquoted and frozen to -80 °C. Plasma 8-Isoprostane 
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levels were measured using the 8-Isoprostane EIA kit according to manufacturer’s protocol 
(Cayman Chemicals; Ann Arbor, MI). The colon was resected, cleaned with phosphate buffered 
saline, and the distal and proximal colonic mucosa was scrapped, collected, and immediately 
frozen in liquid nitrogen and stored at -80 °C for further analysis. Vital organs were removed, 
trimmed of excess fat, and weighed. 
4.3.7 Statistical Analysis. 
 Data are presented as means ± standard error. Statistical analysis was done using SAS 
version 9.3 and significance was determined by one-way ANOVA, followed by the post-hoc 
Fisher least significant difference (LSD) test for multiple means comparisons. Values not sharing 
the same letter were statistically significant (P < 0.05). * Indicates significant difference from 
LFD control (P < 0.05). † Indicates trend from LFD control (P < 0.10). ‡ Indicates significant 
difference from HFD control (P < 0.05). 
4.4 Results and Discussion. 
4.4.1 Sweet Sorghum is Well-tolerated in A/J Mice Fed Low-fat and High-fat Diets.  
 There was no unexpected mortality in animals consuming LFD, HFD, or diets containing 
SS extract at 1% diet for 10 wk. Furthermore, there were no observable adverse events due to 
treatment over the study period. Decreases in feed intake and water intake could be a result of 
toxicity associated with toxic compounds in the diet. As seen in Figure 24, there was no loss of 
feed intake or water intake observed in mice fed SS containing diets when compared to LFD and 
HFD controls. Generally, mice fed HFD + SS diet ate less on average than HFD control animals. 
However, this was not sufficient to cause any detrimental reductions in body weight (Figure 25). 




 Figure 24. Feed and water intakes for A/J mice. Weekly measures were taken through the study. 
Feed intake is presented as mean g of feed intake per kg of animal body weight per day (g/kg/d). 
Water intake is presented as mean mL of water intake per kg of animal body weight per day 
(mL/kg/d). LFD = Low-fat diet control; HFD = High-fat diet control; LFD + SS = LFD with 1% 
sweet sorghum dermal layer extract (SS); HFD + SS = HFD with 1% SS.  
 
between groups after 9 wk of diet. These results mirror those of Nwinyi’s group, who found that 
oral administration of sorghum leaf sheath at 400 mg/kg caused no significant changes in mean 
feed and water intakes, and body weights in rats after 4 wk185.  
The results of organ weights are summarized in Table 13. Except for the uterus, there 
were no significant differences observed in any of the vital and reproductive organs measured 
between diets containing SS and their respective control diets. Our results are in accordance with 




Figure 25. Body weight for A/J mice. Weekly measures of bodyweight were taken throughout the 
study and are presented in mean g of bodyweight. LFD = Low-fat diet control; HFD = High-fat 
diet control; LFD + SS = LFD with 1% sweet sorghum dermal layer extract (SS); HFD + SS = 
HFD with 1% SS. 
 
oral sorghum leaf sheath at 400 mg/kg for 4 wk185. A similar study reported no changes in the 
weights of the liver, spleen, kidneys, and lungs of rats given oral sorghum bran extract at a 
concentration of 5000 mg/kg for 14 d186. There were no effects of HFD or HFD + SS in organ 
weights of male mice (P < 0.05). In female mice, HFD did increase the weight of the liver. This 
may have been a result of liver steatosis which often accompanies HFD feeding in mice. The 
weight of uterus differed significantly between the highly variable HFD (197 ± 107 mg) and 
HFD + SS (64 ± 8 mg). However, neither of these groups differed from LFD fed control animals 
(P < 0.05). A HFD has been demonstrated to increase the incidence of sporadic uterine 
adenocarcinomas in female Donryu rat to 18% while LFD incidence was 0%187. Furthermore, 
this was associated with changes in the estrogen to progesterone ratio and earlier histological 
changes in the uterus as compared to basal diets187. It is therefore plausible uterine weight in 
HFD fed animals is a result of the cancer promoting effects of a HFD. This would explain the  
increased uterine weight in these animals along with the increase in variation, as not all animals 
would develop uterine tumors (only an 18% tumor incidence rate reported187). If this is true, it 
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would then allude to a protective effect of SS in the HFD + SS group, as these animals did not 
show increased uterine weight. However, as the uterus was not a focus of the present study, these 
comments will remain purely the authors’ speculation, and will need to be addressed in future 
studies. When the results from feed intake, water intake, body weight and organ weight are taken 
together, our observations support that consumption of SS was well-tolerated by mice. 
Table 13. Absolute organ weights of male and female A/J mice fed control and test diets. 
 Males 
organ LFD LFD + SS HFD HFD + SS 
colon length (cm) 10.3 ± 0.7 10.1 ± 0.4 9.5 ± 0.3 9.7 ± 0.6 
liver   919 ± 57.8   938 ± 59.6    990 ± 108.2  985 ± 60.4 
kidneys   307 ± 14.8   319 ± 20.6 311 ± 35.9  293 ± 11.8 
lungs 189 ± 8.9   166 ± 10.2 181 ± 19.6  175 ± 12.0 
spleen   64 ± 2.3 70 ± 1.7 63 ± 3.8 65 ± 3.7 
pancreas   137 ± 14.1   130 ± 15.0  137 ± 31.3 129 ± 7.8- 
brain 399 ± 1.8 408 ± 3.0  398 ± 17.6 391 ± 5.0 
testes & epididymides 273 ± 8.7   246 ± 20.7  276 ± 8.7_ 248 ± 4.8 
prostate & seminal 
vesicles 
251 ± 23.1 249 ± 19.6 295 ± 32.2 254 ± 2.3 
 Females 
organ LFD LFD + SS HFD HFD + SS 
colon length (cm) 9.3 ± 0.3  9.2 ± 0.5 9.5 ± 0.3  9.3 ± 0.2 
liver   794 ± 39.5a      849 ± 35.4ab    894 ± 28.6b     924 ± 41.2b 
kidneys  241 ± 13.9   266 ± 12.6   259 ± 12.9    271 ± 19.1 
lungs  164 ± 14.0   168 ± 12.1   165 ± 10.6 154 ± 2.7 
spleen  68 ± 2.4   70 ± 4.0   71 ± 3.6     70 ± 13.4 
pancreas    119 ± 5.8 123 ± 7.4 112 ± 8.2 129 ± 7.8 
brain  396 ± 11.0   403 ± 10.1 399 ± 4.1 389 ± 7.6 
uterus     89 ± 8.4ab      82 ± 5.9ab      197 ± 107.2a     64 ± 7.9b 
ovaries  13 ± 4.0   21 ± 7.6   12 ± 1.8   15 ± 4.5 
LFD = low-fat diet; HFD = high-fat diet; SS = diet containing 1% w/w sweet sorghum dermal 
layer extract.  Data are presented as mean weight ± standard error, except for colon, which is 
presented as mean length ± standard error. Different letters indicate significant differences 
(P < 0.05).   
 
4.4.2 Effects of a High-fat Diet on Body Composition and Glucose Tolerance in A/J Mice. 
 After 9 wk of feeding, A/J mice were subjected to Dual Energy X-ray Absorptiometry 
(DEXA) to assess the effects of HFD on body composition. While there were no significant 
differences in animal weights after 9 wk feeding (Figure 25), DEXA scans (Figure 26) revealed 
that HFD fed mice were significantly fatter than their LFD counterparts. The average body fat 
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percentage of mice fed HFD increased from 20.9% to 27.3% (P < 0.05) and there was a trend for 
an increase in average body fat mass from 4.7 g to 6.4 g fat (P < 0.1). We observed no significant 
differences in the percent body fat or fat mass in mice consuming HFD + SS from HFD, or in 
mice consuming LFD + SS from LFD, which indicates that SS extract is neither pro- nor anti-
obesogenic.  
 
Figure 26. The fat composition of A/J mice after 9 wk of high and low-fat diets with and without 
test compounds as determined by Dual Energy X-ray Absorptiometry. Values are presented as 
mean body fat percentages (% Body Fat) ± standard error and mean grams of body fat (g Body 
Fat) ± standard error, respectively. LFD = Low-fat diet control; HFD = High-fat diet control; LFD 
+ SS = LFD with 1% sweet sorghum dermal layer extract (SS); HFD + SS = HFD with 1% SS. * 
Significantly different compared to LFD (P < 0.05). † Trend compared to LFD (P < 0.05)  
 
 Glucose tolerance tests (GTT) were also performed after 9 wk of feeding and results 
displayed in Figure 27. After 9 wk of feeding, the HFD group demonstrated higher AUC values, 
however, this was not significantly different from LFD control (P = 0.12). This lack of response 
in AUC values in the HFD group may be due to the presence of equal numbers of females in the 
each group. Recent investigations into the role of gender in HFD induced obesity and metabolic 
disorder have revealed that female mice are protected from HFD induced obesity and metabolic 
disorder when compared to their male counterparts188–190. While the mechanism for this is not 
completely understood, it seems that estrogen plays a key role, as ovariectomized mice respond 
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similarly to HFD induced obesity and metabolic disorder as male mice190. HFD + SS group had 
significantly higher AUC values than LFD control. However, this was not different than HFD.  
 
Figure 27. Glucose tolerance tests in A/J mice. Glucose tolerance test was performed in A/J mice 
at wk 9 of the study after a 6 hr fast. Blood glucose (mg/dL) was measured at 0, 15, 30, 60 and 120 
min after initial injection. Area under the curve (AUC) was calculated for each group and presented 
as mean AUC ± standard error. LFD = Low-fat diet control; HFD = High-fat diet control; LFD + 
SS = LFD with 1% sweet sorghum dermal layer extract (SS); HFD + SS = HFD with 1% SS. * 
Significantly different compared to LFD (P < 0.05). 
 
4.4.3 High-fat Diet did not Alter Colonic Inflammation and Barrier Function. 
 HFD induced obesity has been reported to increase intestinal inflammation through 
altering intestinal microbiota, which leads to increased intestinal permeability, resulting in 
activation of toll-like receptors, inducing inflammation in the intestinal mucosa128,191,192. To 
understand the inflammatory changes occurring in the colon of HFD animals, real-time 
quantitative PCR was used to assess the mRNA expression levels for TLR-4, TNF-α, NF-κB, IL-
1β, and IL-6 in the colonic mucosa (Figure 28). There were no differences observed in any of the 
inflammatory markers when comparing HFD to LFD. Our data indicates that HFD feeding does 
not increase colonic inflammation in A/J mice after 10 wk.  
 Recent studies have suggested that intestinal macrophages play important roles in 
maintaining homeostasis by eliminating intestinal pathogens while negatively regulating excess 




Figure 28. Relative mRNA expression levels of TNFα, TLR4, NF-κB, IL-1β, and IL-6 in the distal 
colonic mucosa of A/J mice. The relative expression of each gene was normalized to β-actin. A 
mixture of the cDNA from all samples was used as the calibrator to which all other groups were 
compared using the ΔΔCq method. LFD = Low-fat diet control; HFD = High-fat diet control; LFD 




produce large amounts of antiinflammatory IL-10 and play a central role in regulation of immune 
responses against commensal bacteria194. In addition, these macrophages have been shown to 
produce large amounts of MCP-1, and MCP-1 deficiency caused impaired IL-10 production, 
which exacerbated intestinal inflammation194. Furthermore, it has been shown that these 
populations change during chemically induced colitis194. To assess changes in intestinal 
macrophage populations in HFD fed A/J mice, we used real time quantitative PCR to measure 
mRNA expression of the macrophage marker F4/80 and MCP-1 (Figure 29). Only the mice fed 
HFD + SS differed significantly in F4/80 gene expression from LFD. However, this did not  
 
Figure 29. Relative mRNA expression levels of the macrophage marker F4/80 and MCP-1 in the 
distal colonic mucosa of A/J mice. A mixture of the cDNA from all samples was used as the 
calibrator and normalized to β-actin to which all other groups were compared using the ΔΔCq 
method.  LFD = Low-fat diet control; HFD = High-fat diet control; LFD + SS = LFD with 1% 
sweet sorghum dermal layer extract (SS); HFD + SS = HFD with 1% SS. * Significant differences 
from LFD control (P < 0.05). 
 
seem to alter colonic inflammation as there was no change in colonic inflammatory marker gene 
expression. MCP-1 expression levels were unchanged across all treatment groups. Our data 
suggest that 9 wk of HFD does not alter lamina propria macrophages. 
We investigated the impact of HFD induced colitis on colonic barrier function by 
measuring occludin and ZO-1 mRNA expression levels by qPCR in A/J mice consuming LFD 
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and HFD. HFD has been previously shown to increase intestinal permeability via decreasing 
expression of tight junction proteins128. HFD has been demonstrated to induce changes in gut 
microbiota, leading to an increase in systemic lipopolysaccharide levels, activating toll-like 
receptors in epithelial and immunological cells of the mucosa195. This leads to altered barrier 
function causing inflammation in the lamina propria, which may lead to mesenteric fat 
inflammation196, and ultimately, systemic inflammation as observed by inflammation in liver and 
other organs195. Occludin and ZO-1 are proteins which help to form tight junctions between the 
intestinal epithelial cells. Figure 30 shows the relative mRNA expression for occludin and ZO-1. 
Occludin and ZO-1 levels were not changed by HFD or by the addition of SS to the diets of 
mice. Our data indicate that 9 wk of HFD with or without SS, does not alter colonic barrier 
function.  
Our results from the qPCR analysis of inflammatory markers, macrophage markers, and 
junction proteins demonstrate that a HFD in A/J mice does not alter inflammation in the colon 
after 10 wk of diet. This evidence supports recent investigations, which have indicated that a 
HFD in mice induces intestinal inflammation in the small intestine, but not the colon by 
increasing TNF levels191. 
4.4.4 Addition of Sweet Sorghum Ameliorates High-fat Diet Induced Increases in 
Systemic Oxidative Stress.  
Models of high-fat diet induced obesity, diabetes and hypertension have been shown to 
increase oxidative stress197,198. Isoprostanes are produced non-enzymatically by the sporadic 
oxidation of arachidonic acid in tissue phospholipid199. Therefore, isoprostanes are elevated 




Figure 30. Relative mRNA expression levels of the genes encoding the tight junction proteins 
occludin and ZO-1 in the distal colonic mucosa of A/J mice. The relative expression of each gene 
was normalized to β-actin. A mixture of the cDNA from all samples was used as the calibrator to 
which all other groups were compared using the ΔΔCq method. LFD = Low-fat diet control; HFD 
= High-fat diet control; LFD + SS = LFD with 1% sweet sorghum dermal layer extract (SS); HFD 
+ SS = HFD with 1% SS. 
 
pulmonary and renal vasoconstriction199. 8IP is also known to be increased in HFD models of 
obesity197,198 and increasing consumption of phenolic compounds have been shown to decrease 
oxidative stress as measured by 8IP200,201. We next hypothesized that HFD would cause systemic 
increases in oxidative stress of mice consuming HFD and that SS phenolics would ameliorate 
this increase. Oxidative stress was estimated by the presence of 8IP in mice plasma collected at 
the termination of the study. To our knowledge, this is the first study reporting 8IP plasma levels 
in the A/J background fed LFD and HFD. Figure 31 demonstrates the levels of plasma 8IP in A/J 
mice after 10 wk of study. In the LFD control fed animals, plasma 8-IP was approximately 200 
pg/ml in A/J mice. This is similar to plasma 8-IP levels reported in C57BL/KsJ wild type and 
diabetic db/db of approximately 200 pg/mL and 300 pg/mL, respectively202. HFD fed male and 
female A/J mice had approximately a 2.5-fold increase in plasma 8IP from control from 208 to 
505 pg/mL, which was significantly different from LFD control. This is in agreement with a 
study reporting that the levels of urinary 8-IP was about 3-fold higher in HFD fed rats after 16 
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wk feeding198. In comparison, mice fed HFD + SS had only a 1.4-fold increase in plasma 8IP 
levels (294 pg/mL), which was not statistically different from control (P = 0.351). Similar to 
those of Olayinka’s group182, who demonstrated sorghum leaf sheath extract dose-dependently 
decreased hepatic lipid peroxidation in rats with cadmium-induced oxidative stress, our findings 
support the use of SS as a source of dietary antioxidant with in vivo efficacy.  
 
Figure 31. Sweet sorghum extract ameliorates high-fat diet induced oxidative stress. Oxidative 
stress levels, as assessed by 8-Isoprostane (8-IP), were measured in the plasma collected from A/J 
mice at time of animal sacrifice. The levels of 8-IP were reported as pg of 8-IP per mL of plasma 
(pg/mL). Feeding of high-fat diet (HFD) elevated plasma 8-IP in mice from low-fat diet controls 
(LFD). Addition of 1% sweet sorghum dermal layer extract (SS) to HFD significantly improved 
8-IP levels, indicating its efficacy as an in vivo antioxidant. LFD = Low-fat diet control; HFD = 
High-fat diet control; LFD + SS = LFD with 1% sweet sorghum dermal layer extract (SS); HFD + 
SS = HFD with 1% SS. * Significantly different compared to LFD (P < 0.05). 
 
 In conclusion, ethanolic extract from the stalk of S. bicolor was well-tolerated in mice 
consuming HFD and LFD, as shown by feed intake, water intake, bodyweight and vital organ 
weights. HFD feeding did increase adiposity as measured by DEXA scanning. Addition of SS to 
diets proved to be neither pro- nor anti-obesogenic. HFD feeding resulted in non-significant 
increases in glucose tolerance, as measured by glucose tolerance test, in A/J mice. Furthermore, 
HFD feeding in A/J mice, did not cause changes in colonic inflammation, lamina propria 
macrophages, or intestinal permeability in the colonic mucosa, as determined from qPCR 
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analysis of mRNA gene expression. SS extract was further demonstrated to have in vivo 
antioxidant activity by reducing systemic levels of oxidative stress, as measured by 8-





CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
In this work, we investigated the use of sweet sorghum (Sorghum bicolor) biomass as a 
reservoir of human health-benefiting bioactive compounds in the context of the biorefinery 
approach to biofuel production. We explored the in vitro anticancer properties in colorectal 
cancer cell lines. While the use of aqueous acetone was the most effective extraction solvent for 
sweet sorghum bioactive compounds tested, aqueous ethanol, a GRAS alternative, proved to be 
nearly as efficient an extraction solvent. Furthermore, extracts from aqueous ethanol 
demonstrated greater antiproliferative activities in colon cancer cells, indicating that solvent 
selection is an important factor when extracting anticancer bioactive compounds. These 
investigations further elucidated strong antiproliferative and proapoptotic activities of sweet 
sorghum component with pith < leaf < dermal < seed head. Investigations into molecular 
mechanisms revealed dermal and seed head extracts to function partly through altering β-catenin 
and β-catenin’s down-stream prosurvival targets. This activity was deemed dependent upon 
functional p53 presence for dermal extract and partially p53-dependent for seed head extract.  
We also assessed in vivo bioactivity of the less consumed sweet sorghum stalk dermal 
layer component in a murine western style diet model of obesity and oxidative stress. Sweet 
sorghum dermal layer was well-tolerated in mice fed both high-fat and low-fat diets with extract 
at 1% w/w. This was indicated by normal levels of feed intake, water intake, body weight and 
organ weights in mice consuming dermal layer extract. Results further show that sweet sorghum 
dermal layer demonstrated antioxidant properties in mice fed high-fat diets for 10 weeks.   
Having demonstrated a wide range of bioactivity in vitro and in vivo in sweet sorghum 
biomass, further research is now needed to assess the safety and anticancer activities of these 
extracts in pre-clinical models of colorectal cancer. Two such models are the azoxymethane-
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induced sporadic colon cancer rodent model and the western diet induced sporadic colon cancer 
rodent model. With these and other models, it may be possible to elucidate in vivo anticancer 
activity of sweet sorghum extracts. They could further assess the molecular mechanisms 
responsible for the observed activities, such as the β-catenin signaling pathway, which we 
observed to be positively altered and associated with anticancer activity of sweet sorghum 
extracts in vitro. If proven successful, clinical trials would then be required. Further research is 
also needed for the scaling up and validation of extraction methods to be implemented in large 
scale production facilities to ensure minimal losses in bioactivity of sweet sorghum extracts. 
Such research would also provide much needed insights into the economical and cost-benefit 
assessments for sweet sorghum extract producers.  
In conclusion, sweet sorghum is an important agricultural crop with great promise for 
sustainable biofuel production. When implementing the biorefinery approach to biofuel 
production, the biomass from sweet sorghum may also serve as an important reservoir for 
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